BindingDB logo
myBDB logout

Search by Patent Identification


Patent: (prefix with "US" like US6078908)
PatentDataCompoundsHGNC
(for human-derived proteins)
Patent TitleOrganizationDepositionDownloads
US10301320 27 25 HGNC:5154 Compositions and methods of modulating 15-PGDH activity University of Kentucky Research Foundation; Case Western Reserve University; Board of Regents of the University of Texas System 03/26/202D 3D TSV
US10301305 252 63 Heteroaromatic derivatives and their use as pharmaceuticals MUTABILIS 03/26/202D 3D TSV
US10301323 183 61 HGNC:4852 HGNC:4854 HGNC:4853 Histone deacetylase inhibitors BIOMARIN PHARMACEUTICAL INC. 03/26/202D 3D TSV
US10301291 31 31 HGNC:6872 Imidazole derivative having JNK inhibitory activity and use thereof SAMJIN PHARMACEUTICAL CO., LTD. 03/26/202D 3D TSV
US10301317 373 365 HGNC:6871 Inhibitors of ERK and methods of use KURA ONCOLOGY, INC. 03/26/202D 3D TSV
US10301288 61 15 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 Kinase inhibitors Topivert Pharma Limited 03/26/202D 3D TSV
US10301336 33 33 HGNC:2771 Phosphonate compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 03/26/202D 3D TSV
US10301286 79 33 HGNC:6932 HGNC:6929 HGNC:6931 Piperazine derivative Astellas Pharma Inc. 03/26/202D 3D TSV
US10301306 185 180 HGNC:10021 Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors Bristol-Myers Squibb Company 03/26/202D 3D TSV
US10301297 63 62 HGNC:1133 Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease Guangzhou Innocare Pharma Tech Co., Ltd. 03/26/202D 3D TSV
US10301284 141 139 HGNC:6371 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. 03/26/202D 3D TSV
US10301278 58 54 HGNC:9644 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 Novartis AG 03/25/202D 3D TSV
US10300056 14 14 HGNC:9843 CGRP receptor antagonists Heptares Therapeutics Limited 03/25/202D 3D TSV
US10301272 844 306 Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] Phenex Pharmaceuticals AG 03/25/202D 3D TSV
US10301280 257 153 HGNC:6342 Compounds and methods for kinase modulation, and indications therefor Plexxikon Inc. 03/25/202D 3D TSV
US10300051 61 61 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 03/25/202D 3D TSV
US10301269 41 41 HGNC:3827 Imidazole derivatives as formyl peptide receptor modulators ALLERGAN, INC. 03/25/202D 3D TSV
US10300066 119 118 HGNC:1133 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors Zhejiang DTRM Biopharma Co. Ltd. 03/25/202D 3D TSV
US10300067 53 53 HGNC:644 Tetrahydropyridopyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. 03/25/202D 3D TSV
US10301253 203 87 HGNC:29079 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 03/25/202D 3D TSV
US10300048 73 53 HGNC:3553 Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation UNIVERSITAT BERN 03/25/202D 3D TSV
US10300060 43 43 HGNC:8031 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. 03/25/202D 3D TSV
US10300058 50 18 HGNC:3236 Tyrosine kinase inhibitor and uses thereof Xuanzhu Pharma Co., Ltd. 03/25/202D 3D TSV
US10300074 114 40 HGNC:13702 Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE; SALK INSTITUTE FOR BIOLOGICAL STUDIES 03/25/202D 3D TSV
US9957268 196 88 HGNC:13575 1H-pyrrolo[2,3,c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins Incyte Corporation 03/23/202D 3D TSV
US9956214 208 103 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum University of Washington Through its Center for Commercialization 03/23/202D 3D TSV
US9957261 118 59 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives Hoffman-La Roche Inc. 03/23/202D 3D TSV
US9957235 248 139 Benzimidazol-2-amines as mIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 03/23/202D 3D TSV
US9957263 371 184 HGNC:13575 Bromodomain inhibitors AbbVie Inc. 03/23/202D 3D TSV
US9957276 44 44 HGNC:1771 CDK inhibitors GI Therapeutics, Inc. 03/23/202D 3D TSV
US9956208 4 4 HGNC:1133 Compounds for the treatment of cancer and inflammatory diseases TBA 03/23/202D 3D TSV
US9957264 938 423 HGNC:6190 HGNC:6192 Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors Merck Sharp & Dohme Corp. 03/23/202D 3D TSV
US9957265 226 75 HGNC:6190 HGNC:6192 N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors Merck Sharp & Dohme Corp. 03/23/202D 3D TSV
US9956192 42 21 HGNC:4852 HGNC:14064 Selective histone deactylase 6 inhibitors H. Lee Moffitt Cancer Center and Research Institute, Inc.; Board of Trustees of The University of Illinois 03/23/202D 3D TSV
US9951056 63 61 HGNC:1133 Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease BEIJING INNOCARE PHARMA TECH CO., LTD. 03/18/202D 3D TSV
US9951063 147 147 HGNC:4540 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives IDORSIA PHARMACEUTICALS LTD 03/16/202D 3D TSV
US9951077 118 116 HGNC:1133 Aminopyridazinone compounds as protein kinase inhibitors Jiangsu Hengrui Medicine Co., Ltd. 03/16/202D 3D TSV
US9951027 390 346 Benzimidazol-2-amines as MIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 03/16/202D 3D TSV
US9951071 443 219 HGNC:6371 HGNC:3529 Dihydropyridone P1 as factor XIa inhibitors Bristol-Myers Squibb Company 03/16/202D 3D TSV
US9951026 13 13 HGNC:3357 Heterocyclic vinyl autotaxin inhibitor compounds PHARMAKEA, INC. 03/16/202D 3D TSV
US9951068 271 154 HGNC:6251 HGNC:550 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN LIMITED 03/16/202D 3D TSV
US9951086 310 305 HGNC:17967 Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments BAYER PHARMA AKTIENGESELLSCHAFT 03/16/202D 3D TSV
US9949975 25 25 HGNC:933 Inhibitors of beta-secretase Vitae Pharmaceuticals, Inc. 03/16/202D 3D TSV
US9951048 488 236 HGNC:4617 HGNC:3091 Isoquinolin-3-yl carboxamides and preparation and use thereof Samumed, LLC 03/16/202D 3D TSV
US9951014 113 35 HGNC:7872 HGNC:7873 Mammalian and bacterial nitric oxide synthase inhibitors Northwestern University 03/16/202D 3D TSV
US9949951 29 28 HGNC:6059 Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors ITEOS THERAPEUTICS 03/16/202D 3D TSV
US9951035 6 3 HGNC:7175 HGNC:7176 Selective matrix metalloproteinase inhibitors University of Notre Dame du Lac 03/16/202D 3D TSV
US9951029 63 63 HGNC:3765 Styryl quinazoline derivatives as pharmaceutically active agents Vichem Chemie Kutató Kft. 03/16/202D 3D TSV
US9951033 23 23 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO 03/16/202D 3D TSV
US9944601 159 43 HGNC:6833 HGNC:6834 HGNC:29079 (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors ORYZON GENOMICS, S.A. 03/12/202D 3D TSV
US9944646 114 109 HGNC:8977 Bicyclic azaheterocyclobenzylamines as PI3K inhibitors Incyte Holdings Corporation; Incyte Corporation 03/12/202D 3D TSV
US9944606 9 5 HGNC:2160 HGNC:2159 Cannabinoid receptor modulators Arena Pharmaceuticals, Inc. 03/12/202D 3D TSV
US9944643 8 8 HGNC:3529 Factor XIa inhibitors Merck Sharp & Dohme Corp. 03/12/202D 3D TSV
US9944647 138 138 HGNC:29079 Heterocyclic compounds as LSD1 inhibitors Incyte Corporation 03/12/202D 3D TSV
US9944645 205 205 HGNC:7029 Imidazotriazines and imidazopyrimidines as kinase inhibitors Incyte Corporation; Incyte Holdings Corporation 03/12/202D 3D TSV
US9944618 940 167 HGNC:6251 HGNC:11050 HGNC:2637 HGNC:2625 HGNC:11048 HGNC:11049 Inhibiting neurotransmitter reuptake Mayo Foundation for Medical Education and Research; Virginia Tech Intellectual Properties, Inc. 03/12/202D 3D TSV
US9943516 19 17 HGNC:17967 Inhibitors of IRAK4 activity Merck Sharp & Dohme Corp. 03/12/202D 3D TSV
USRE46792 103 103 HGNC:8783 Oxazole compound and pharmaceutical composition Otsuka Pharmaceutical Co., Ltd. 03/12/202D 3D TSV
US9944624 126 61 HGNC:17432 HGNC:1936 Substituted amino triazoles useful as human chitinase inhibitors OncoArendi Therapeutics S.A. 03/12/202D 3D TSV
US10294221 63 57 1, 3, 4-thiadiazole compounds and their use in treating cancer AstraZeneca AB; Cancer Research Technology Limited 03/10/202D 3D TSV
US10294230 48 11 HGNC:4586 HGNC:4585 HGNC:6251 HGNC:2625 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited 03/10/202D 3D TSV
US10294218 165 150 HGNC:1780 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity VIROSTATICS SRL 03/10/202D 3D TSV
US10294227 332 21 HGNC:11283 HGNC:12841 HGNC:9617 HGNC:8803 HGNC:4840 HGNC:6735 HGNC:3697 HGNC:4037 HGNC:1057 HGNC:76 HGNC:6342 HGNC:3955 HGNC:3942 HGNC:9967 HGNC:6524 Compounds UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH 03/10/202D 3D TSV
US10292975 2 2 Compounds as rearranged during transfection (RET) inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 03/10/202D 3D TSV
US10294217 35 27 HGNC:1950 Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators Suven Life Sciences Limited 03/10/202D 3D TSV
US10294229 444 398 HGNC:17967 Heteroaryl substituted aminopyridine compounds Bristol-Myers Squibb Company 03/10/202D 3D TSV
US10294212 277 273 HGNC:27269 HGNC:6059 Inhibitors of the kynurenine pathway CURADEV PHARMA, PVT. LTD. 03/10/202D 3D TSV
US10292981 53 47 HGNC:6001 Oxazoline and isoxazoline derivatives as CRAC modulators LUPIN LIMITED 03/10/202D 3D TSV
US10294259 6 3 HGNC:11037 HGNC:11036 Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof Tianjin Institute of Pharmaceutical Research 03/10/202D 3D TSV
US10294214 80 80 HGNC:6932 Positive allosteric modulators of human melanocortin-4 receptor Vanderbilt University; King''s College London; Glaxo Group Limited 03/10/202D 3D TSV
US10294223 197 129 HGNC:3689 HGNC:3688 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. 03/10/202D 3D TSV
US10294226 60 15 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Small molecule inhibitors of the JAK family of kinases Janssen Pharmaceutica NV 03/10/202D 3D TSV
US10294246 271 135 HGNC:9542 HGNC:9545 Substituted boronic acids and boronate esters as immunoproteasome inhibitors MERCK PATENT GMBH 03/10/202D 3D TSV
US10292985 72 36 HGNC:11772 HGNC:11773 TGF beta receptor antagonists Bristol-Myers Squibb Company 03/10/202D 3D TSV
US9938265 43 33 1,3,4-thiadiazole compounds and their use in treating cancer AstraZeneca AB; Cancer Research Technology Limited 03/02/202D 3D TSV
US9938276 164 81 HGNC:4849 HGNC:4848 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists Merck Sharp & Dohme Corp. 03/02/202D 3D TSV
US9938268 34 34 HGNC:11393 C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof Merck Patent GmbH 03/02/202D 3D TSV
US9938222 129 116 HGNC:19061 Cyclopropanecarboxylic acid GPR120 modulators Bristol-Myers Squibb Company 03/02/202D 3D TSV
US9938267 694 668 Heterocyclic inhibitors of glutaminase Calithera Biosciences, Inc. 03/02/202D 3D TSV
US9938272 109 34 HGNC:9475 HGNC:3528 HGNC:3535 Hydrazine compound as blood coagulation factor Xa inhibitor North China Pharmaceutical Company., Ltd. 03/02/202D 3D TSV
US9938274 44 22 HGNC:6307 HGNC:7029 Naphthyridine compounds, medical combinations and use thereof NANJING NATINEFY PHARMATECH CO., LTD.; WUHAN NOVAFFEY SCIENCE & TECHNOLOGY CO., LTD. 03/02/202D 3D TSV
US9938257 57 25 HGNC:6190 HGNC:6192 HGNC:11393 HGNC:11390 HGNC:3765 Substituted heteroaryl compounds and methods of use CALITOR SCIENCES, LLC; SUNSHINE LAKE PHARMA CO., LTD. 03/02/202D 3D TSV
US9938289 9 9 HGNC:11772 Therapeutic pyrazolyl thienopyridines FBM THERAPEUTICS, LLC 03/02/202D 3D TSV
US9938290 52 13 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors Karus Therapeutics Limited 03/02/202D 3D TSV
US10287286 262 260 HGNC:14660 Compounds Takeda Pharmaceutical Company Limited 02/29/202D 3D TSV
US9931340 68 66 HGNC:2671 Pyridazinone compounds and their use as DAAO inhibitors Takeda Pharmaceutical Company Limited 02/29/202D 3D TSV
US10285983 70 70 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof Samumed, LLC 02/27/202D 3D TSV
US10285982 66 66 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof Samumed, LLC 02/27/202D 3D TSV
US10287274 43 43 HGNC:5302 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 02/27/202D 3D TSV
US10287270 3 3 HGNC:550 Amino pyrimidine SSAO inhibitors ELI LILLY AND COMPANY 02/27/202D 3D TSV
US10287301 719 698 HGNC:2771 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. 02/27/202D 3D TSV
US10287293 45 22 HGNC:8777 Bicyclic heterocyclic compounds as PDE2 inhibitors Merck Sharp & Dohme Corp. 02/27/202D 3D TSV
US10287292 184 129 HGNC:23692 CXCR7 antagonists ChemoCentryx, Inc. 02/27/202D 3D TSV
US10287258 37 37 HGNC:2528 Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB 02/27/202D 3D TSV
US10287278 40 14 HGNC:6026 HGNC:6027 Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies GALDERMA RESEARCH & DEVELOPMENT 02/27/202D 3D TSV
US10285988 30 30 HGNC:15983 Compounds for treatment of fibrosis diseases CUREGENIX, INC. 02/27/202D 3D TSV
US10287300 130 64 HGNC:28426 Heterocyclic derivatives as modulators of kinase activity Merck Patent GmbH 02/27/202D 3D TSV
US10287268 8 4 HGNC:4840 HGNC:1133 Imidazolyl kinase inhibitors and uses thereof Dana-Farber Cancer Institute, Inc. 02/27/202D 3D TSV
US10287279 42 39 HGNC:433 Inhibitors of human 12/15-lipoxygenase THE CHILDREN''S HOSPITAL CORPORATION; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services 02/27/202D 3D TSV
US10287267 951 304 HGNC:4617 HGNC:3091 Isoquinolin-3-yl carboxamides and preparation and use thereof Samumed, LLC 02/27/202D 3D TSV
US10287250 110 35 HGNC:8156 Morphan and morphinan analogues, and methods of use ALKERMES PHARMA IRELAND LIMITED 02/27/202D 3D TSV
US10285989 371 197 HGNC:8777 Pyrimidinone amide compounds as PDE2 inhibitors Merck Sharp & Dohme Corp. 02/27/202D 3D TSV
US10287272 149 126 HGNC:10260 Substituted indazole compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 02/27/202D 3D TSV
US10287305 266 261 HGNC:4849 Substituted piperidine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 02/27/202D 3D TSV
US10287253 52 51 HGNC:15631 Substituted pyrimidines containing acidic groups as TLR7 modulators APROS THERAPEUTICS, INC. 02/27/202D 3D TSV
US10287295 605 303 HGNC:11773 TGF-β inhibitors Rigel Pharmaceuticals, Inc.; Bristol-Meyers Squibb Company 02/27/202D 3D TSV
US10280166 126 125 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof Samumed, LLC 02/24/202D 3D TSV
US9932329 28 14 HGNC:6171 HGNC:12434 Benzimidazole derivatives as RLK and ITK inhibitors PRINCIPIA BIOPHARMA, INC. 02/24/202D 3D TSV
US9932325 215 166 Compounds, compositions, and methods Denali Therapeutics Inc. 02/24/202D 3D TSV
US9932332 2 2 HGNC:7967 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. 02/24/202D 3D TSV
US10280171 183 98 HGNC:3255 Heterocyclic inhibitors of PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 02/24/202D 3D TSV
US10280184 71 69 HGNC:1133 HGNC:2433 Heterocyclic kinase inhibitors AbbVie Inc. 02/24/202D 3D TSV
US9932350 108 101 HGNC:17967 Inhibitors of IRAK4 activity Merck Sharp & Dohme Corp. 02/24/202D 3D TSV
US10280167 39 39 Purine derivatives for the treatment of viral infections Janssen Sciences Ireland UC 02/24/202D 3D TSV
US9932327 10 5 HGNC:1780 HGNC:1771 Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof The Council of Scientific & Industrial Research 02/24/202D 3D TSV
US9931338 7 7 HGNC:11491 Syk inhibitors Gilead Sciences, Inc. 02/24/202D 3D TSV
US9932341 125 112 HGNC:8977 Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders Incyte Corporation; Incyte Holdings Corporation 02/24/202D 3D TSV
US10278968 15 15 Combination therapy with glutaminase inhibitors Calithera Biosciences, Inc. 02/21/202D 3D TSV
US10278929 41 36 HGNC:12405 Identification of stabilizers of multimeric proteins The Board of Trustees of the Leland Stanford Junior University 02/21/202D 3D TSV
US10280160 31 26 HGNC:1884 Phthalazinone compounds and methods for the treatment of cystic fibrosis FLATLEY DISCOVERY LAB, LLC 02/21/202D 3D TSV
US10280164 16 16 HGNC:6863 Pyrazolopyridone compounds and uses thereof Incyte Corporation 02/21/202D 3D TSV
US10280144 213 213 HGNC:10260 Pyridazine derivatives as RORc modulators Genentech, Inc. 02/21/202D 3D TSV
US10280165 40 40 Pyridopyrimidinones and methods of use thereof Genentech, Inc. 02/21/202D 3D TSV
US10280150 297 183 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors FORMA TM2, INC. 02/21/202D 3D TSV
US10280174 3 2 HGNC:1133 HGNC:3236 Salt of fused pyrimidine compound and crystal thereof TAIHO PHARMACEUTICAL CO., LTD. 02/21/202D 3D TSV
US10278975 186 172 HGNC:6871 Serine/threonine kinase inhibitors GENENTECH, INC. 02/21/202D 3D TSV
US10280149 220 219 HGNC:13610 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 02/21/202D 3D TSV
US10278962 24 11 HGNC:11177 HGNC:11178 Tricyclic analogues, preparation method and uses thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 02/21/202D 3D TSV
US10273234 26 26 HGNC:3357 Compounds that are S1P modulating agents and/or ATX modulating agents BIOGEN MA INC. 02/20/202D 3D TSV
US10273222 604 163 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 Histone demethylase inhibitors CELGENE QUANTSCEL RESEARCH, INC. 02/20/202D 3D TSV
US10272074 477 475 HGNC:7978 Inhibitors of glucocorticoid receptor translocation SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 02/20/202D 3D TSV
US10273211 24 5 HGNC:3763 HGNC:6307 HGNC:11390 HGNC:3767 HGNC:7029 HGNC:9967 HGNC:3765 Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Exelixis, Inc. 02/20/202D 3D TSV
US10272079 361 180 HGNC:11073 NHE3-binding compounds and methods for inhibiting phosphate transport ARDELYX, INC. 02/20/202D 3D TSV
US10272095 87 83 HGNC:2874 NRF2 regulators GlaxoSmithKline Intellectual Propert Development Limited; Astex Therapeutics, Limited 02/20/202D 3D TSV
US10272077 14 14 Piperidinone carboxamide azaindane CGRP receptor antagonists Merck Sharp & Dohme Corp. 02/20/202D 3D TSV
US10272087 50 8 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Pteridines as FGFR inhibitors ASTEX THERAPEUTICS LTD 02/20/202D 3D TSV
US10273225 22 21 HGNC:4515 Pyrazines as modulators of GPR6 Takeda Pharmaceutical Company Limited 02/20/202D 3D TSV
US10273223 391 389 HGNC:3527 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme, Inc. 02/20/202D 3D TSV
US10273244 348 173 HGNC:3023 HGNC:3024 Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators INDIVIOR UK LIMITED 02/20/202D 3D TSV
US10273230 16 15 HGNC:19061 Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof Piramal Enterprises Limited 02/20/202D 3D TSV
US10273214 78 39 HGNC:4588 HGNC:4587 HGNC:4586 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions Emory University 02/20/202D 3D TSV
US10273259 881 804 Tricyclic sulfones as RORγ modulators Bristol-Myers Squibb Company 02/20/202D 3D TSV
US9890168 32 15 HGNC:3236 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof Shanghai Haiyan Pharmaceutical Technology Co., Ltd.; Yangtze River Pharmaceutical Group Co., Ltd. 02/16/202D 3D TSV
US9890171 200 130 HGNC:2592 Aldosterone synthase inhibitors Boehringer Ingelheim International GmbH 02/16/202D 3D TSV
US9890124 46 23 HGNC:15631 HGNC:15632 Benzazepine sulfonamide compounds Hoffmann-La Roche Inc. 02/16/202D 3D TSV
US9890162 156 52 HGNC:19310 HGNC:8987 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors Incyte Corporation 02/16/202D 3D TSV
US9890156 152 37 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 02/16/202D 3D TSV
US9890160 3 3 HGNC:550 Compounds I PROXIMAGEN LIMITED 02/16/202D 3D TSV
US9890166 638 168 HGNC:13575 HGNC:1103 HGNC:2348 HGNC:1104 Imidazopyrrolidine derivatives and their use in the treatment of disease NOVARTIS AG 02/16/202D 3D TSV
US9890185 468 169 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 Urea derivatives useful as kinase inhibitors Respivert Limited; Topivert Pharma Limited 02/16/202D 3D TSV
US9926281 1937 451 HGNC:7160 HGNC:195 HGNC:7155 HGNC:7166 HGNC:7159 HGNC:221 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis GALAPAGOS NV; LES LABORATOIRES SERVIER 02/10/202D 3D TSV
US9926301 28 13 Bipyrazole derivatives as JAK inhibitors Incyte Corporation 02/10/202D 3D TSV
US9926306 34 33 Inhibition of MCL-1 and/or BFL-1/A1 Dana-Farber Cancer Institute, Inc. 02/10/202D 3D TSV
US9926330 55 53 HGNC:17967 Inhibitors of IRAK4 activity MERCK SHARP & DOHME CORP. 02/10/202D 3D TSV
US9926299 34 34 HGNC:1133 Inhibitors of bruton's tyrosine kinase Centaurus BioPharma Co., Ltd. 02/10/202D 3D TSV
US9926282 826 401 HGNC:10251 HGNC:10252 Phthalazinones and isoquinolinones as rock inhibitors Bristol-Myers Squibb Company 02/10/202D 3D TSV
US9926318 58 53 HGNC:3357 Tetracyclic autotaxin inhibitors PHARMAKEA, INC. 02/10/202D 3D TSV
USRE47351 11 11 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists Gilead Sciences, Inc. 02/07/202D 3D TSV
US10266528 23 22 HGNC:1133 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof Merck Patent GmbH 02/07/202D 3D TSV
US10266537 116 27 HGNC:6613 HGNC:3763 HGNC:11724 HGNC:6735 HGNC:4037 HGNC:3386 HGNC:5960 HGNC:6859 HGNC:9829 HGNC:3689 HGNC:6873 HGNC:7027 HGNC:3767 HGNC:2730 HGNC:7029 HGNC:3688 HGNC:2731 HGNC:6192 HGNC:8031 HGNC:12841 HGNC:9617 HGNC:8803 HGNC:4840 HGNC:3430 HGNC:6307 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:3395 HGNC:77 HGNC:1097 HGNC:76 HGNC:3393 HGNC:3955 HGNC:3236 HGNC:2444 HGNC:1974 HGNC:6524 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof St. Chuan University 02/07/202D 3D TSV
US10265310 158 71 HGNC:3827 HGNC:3826 6-membered cyclic amines or lactames substituted with urea and phenyl GrÜNENTHAL GMBH 02/07/202D 3D TSV
US10266550 64 26 HGNC:11986 HGNC:11989 Bacterial topoisomerase I inhibitors with antibacterial activity THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES; UNIVERSITY OF HAWAII 02/07/202D 3D TSV
US10259818 114 109 HGNC:8977 Bicyclic azaheterocyclobenzylamines as PI3K inhibitors Incyte Corporation; Incyte Holdings Corporation 02/07/202D 3D TSV
US10266560 65 64 HGNC:7967 Bile acid analogs as FXR/TGR5 agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. 02/07/202D 3D TSV
US10259776 16 13 HGNC:4685 Branched 3-phenylpropionic acid derivatives and their use Bayer Intellectual Property GmbH 02/07/202D 3D TSV
US10266513 190 134 HGNC:1133 HGNC:3236 Bruton's tyrosine kinase inhibitors Pfizer Inc. 02/07/202D 3D TSV
US10266491 200 168 HGNC:1133 Carbazole derivatives Bristol-Myers Squibb Company 02/07/202D 3D TSV
US10266496 160 118 HGNC:12805 HGNC:17989 Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof SUNSHINE LAKE PHARMA CO., LTD. 02/07/202D 3D TSV
US10259816 26 26 HGNC:427 Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. 02/07/202D 3D TSV
US10266542 19 18 HGNC:3527 EZH2 inhibitors Mirati Therapeutics, Inc. 02/07/202D 3D TSV
US10266535 56 29 HGNC:1133 HGNC:3765 Inhibitor of FLT3 kinase and use thereof HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES; HEFEI COSOURCE PHARMACEUTICAL CO., LTD. 02/07/202D 3D TSV
US10259786 8 4 HGNC:3023 Psychotropic agents and uses thereof LB PHARMACEUTICALS INC. 02/07/202D 3D TSV
US10266526 956 932 HGNC:15513 HGNC:20982 Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer EPIZYME, INC. 02/07/202D 3D TSV
US10266548 211 187 HGNC:1148 Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases Bayer Intellectual Property GmbH; Bayer Pharma Aktiengesellschaft 02/07/202D 3D TSV
US10259811 517 258 HGNC:11584 HGNC:14552 Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. 02/07/202D 3D TSV
US10266515 202 144 HGNC:6371 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. 02/07/202D 3D TSV
US10265307 324 106 HGNC:19310 HGNC:8987 Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors Incyte Corporation; Incyte Holdings Corporation 02/07/202D 3D TSV
US10266493 71 70 HGNC:17989 Thioacetate compounds, compositions and methods of use Ardea Biosciences, Inc. 02/07/202D 3D TSV
US10266549 345 343 HGNC:12558 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES; SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE; YALE UNIVERSITY 02/07/202D 3D TSV
US9918985 181 155 Compounds and their use as BACE inhibitors ASTRAZENECA AB 02/04/202D 3D TSV
US9920047 375 109 HGNC:6833 HGNC:6834 HGNC:29079 Cyclopropanamine compound and use thereof Takeda Pharmaceutical Company Limited 02/04/202D 3D TSV
US9920032 510 168 HGNC:19310 HGNC:8987 Heterocyclic compounds useful as pim kinase inhibitors Incyte Corporation 02/04/202D 3D TSV
US9920031 261 218 HGNC:1133 Indole carboxamide compounds Bristol-Myers Squibb Company 02/04/202D 3D TSV
US9920038 62 30 HGNC:4849 Methyl oxazole orexin receptor antagonists Merck Sharp & Dohme Corp. 02/04/202D 3D TSV
US9920054 104 104 HGNC:10260 Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof Pfizer Inc. 02/04/202D 3D TSV
US9920053 130 35 HGNC:6251 HGNC:11050 HGNC:11048 HGNC:11049 N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system CHRONOS THERAPEUTICS LIMITED 02/04/202D 3D TSV
US9920060 80 79 HGNC:3430 Pyrazolo[3,4-d]pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. 02/04/202D 3D TSV
US9918974 2 2 Pyridone derivatives as rearranged during transfection (RET) kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 02/04/202D 3D TSV
US9918969 16 14 HGNC:3529 Substituted oxopyridine derivatives and use thereof as factor XIa/plasma Bayer Pharma Aktiengesellschaft 02/04/202D 3D TSV
US9918990 226 111 HGNC:13575 HGNC:1103 Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors Incyte Corporation 02/04/202D 3D TSV
US9914735 391 78 HGNC:11491 HGNC:11390 HGNC:4617 HGNC:3765 Heteroaryl Syk inhibitors Boehringer Ingelheim International GmbH 01/30/202D 3D TSV
US9914707 30 30 HGNC:6307 Naphthylamide compound, preparation method and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 01/30/202D 3D TSV
US9914731 293 156 HGNC:7029 Pyrazolo[1,5-a]pyridine derivatives and methods of their use IGNYTA, INC. 01/30/202D 3D TSV
US9914736 114 113 HGNC:8031 TrKA kinase inhibitors, compositions and methods thereof Merck Sharp & Dohme Corp. 01/30/202D 3D TSV
US9914740 420 404 HGNC:10252 Tricyclic pyrido-carboxamide derivatives as rock inhibitors Bristol-Myers Squibb Company 01/30/202D 3D TSV
US9914721 22 11 HGNC:4849 HGNC:4848 Use of benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD 01/30/202D 3D TSV
US9908875 45 45 HGNC:6857 Apoptosis signal-regulating kinase inhibitors GILEAD SCIENCES, INC. 01/27/202D 3D TSV
US9908845 68 65 HGNC:12680 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. 01/27/202D 3D TSV
US9908886 266 132 HGNC:7110 HGNC:7111 Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof Agency for Science, Technology and Research 01/27/202D 3D TSV
US9908899 143 48 HGNC:4852 HGNC:4854 HGNC:4853 Histone deacetylase inhibitors BIOMARIN PHARMACEUTICAL INC. 01/27/202D 3D TSV
US9908865 511 154 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 01/27/202D 3D TSV
US9907800 460 198 HGNC:11393 HGNC:11390 HGNC:11397 HGNC:3765 Kinase inhibitors and method of treating cancer University Health Network 01/27/202D 3D TSV
US9908872 19 8 HGNC:1133 HGNC:4195 HGNC:7972 Methods to treat lymphoplasmacytic lymphoma Dana-Farber Cancer Institute, Inc. 01/27/202D 3D TSV
US9908897 306 84 HGNC:6251 HGNC:11050 HGNC:11048 HGNC:11049 Spirocyclic derivatives CHRONOS THERAPEUTICS LIMITED 01/27/202D 3D TSV
US9908895 196 88 HGNC:6190 HGNC:6192 Tricyclic fused thiophene derivatives as JAK inhibitors Incyte Corporation 01/27/202D 3D TSV
US10246444 134 32 HGNC:3432 HGNC:3430 HGNC:3236 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions SABILA BIOSCIENCES LLC 01/21/202D 3D TSV
US10246442 135 135 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV 01/21/202D 3D TSV
US10253018 41 41 HGNC:6857 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. 01/21/202D 3D TSV
US9896418 68 65 HGNC:12680 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. 01/21/202D 3D TSV
US9903855 20 5 HGNC:5960 HGNC:11584 HGNC:14552 HGNC:1974 Assays for screening for or identifying an agent or molecule that can block or inhibit AVB3 integrin from forming a complex with KRAS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 01/21/202D 3D TSV
US9896444 175 101 Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 Novartis AG 01/21/202D 3D TSV
US10246453 1146 330 HGNC:10593 HGNC:10585 HGNC:10596 Benzenesulfonamide compounds and their use as therapeutic agents Xenon Pharmaceuticals Inc. 01/21/202D 3D TSV
US9902722 237 235 HGNC:19679 Biaryl kinase inhibitors Bristol-Myers Squibb Company 01/21/202D 3D TSV
US10251892 856 186 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 01/21/202D 3D TSV
US10246462 92 88 HGNC:1605 Chemokine receptor modulators and uses thereof FLX BIO, INC. 01/21/202D 3D TSV
US9896458 251 243 Compounds, compositions and methods Denali Therapeutics Inc. 01/21/202D 3D TSV
US10253017 22 9 HGNC:7856 HGNC:263 HGNC:264 Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors PALOBIOFARMA, S.L. 01/21/202D 3D TSV
US10246466 54 18 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 HGNC:8032 HGNC:8033 HGNC:427 Diaryl macrocycles as modulators of protein kinases TP Therapeutics, Inc. 01/21/202D 3D TSV
US9895376 116 57 Fused tricyclic compounds as Raf kinase inhibitors BEIGENE, LTD. 01/21/202D 3D TSV
US9896436 329 106 HGNC:29012 HGNC:13606 HGNC:17071 HGNC:18039 HGNC:20672 HGNC:13610 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 01/21/202D 3D TSV
US10246456 686 509 HGNC:17967 IRAK4 inhibiting agents BIOGEN MA INC. 01/21/202D 3D TSV
US10253004 54 53 HGNC:4498 Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof Boehringer Ingelheim International GmbH 01/21/202D 3D TSV
US10246457 56 28 HGNC:1133 Indazole and azaindazole Btk inhibitors Merck Sharp & Dohme Corp. 01/21/202D 3D TSV
US10252984 51 51 HGNC:4545 Inhibiting G protein coupled receptor 6 kinase polypeptides Mayo Foundation for Medical Education and Research 01/21/202D 3D TSV
US9902719 31 31 HGNC:29079 Inhibitors of lysine specific demethylase-1 Celgene Quanticel Research, Inc. 01/21/202D 3D TSV
US9902741 68 46 HGNC:8031 Macrocyclic compounds as TRK kinase inhibitors Array BioPharma Inc. 01/21/202D 3D TSV
US10251893 230 227 HGNC:15983 N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators Novartis AG 01/21/202D 3D TSV
US9896435 31 31 HGNC:8031 N-pyrrolidinyl,N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors Array BioPharma Inc. 01/21/202D 3D TSV
US9902709 13 13 HGNC:6307 Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition PEKING UNIVERSITY FOUNDER GROUP CO., LTD.; PKUCARE PHARMACEUTICAL R & D CENTER; PKU HEALTHCARE INDUSTRY GROUP CO., LTD. 01/21/202D 3D TSV
US10253015 169 85 Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA TM2, INC. 01/21/202D 3D TSV
US9902726 5 4 HGNC:8154 HGNC:8156 Pyridone-sulfone morphinan analogs as opioid receptor ligands Purdue Pharma L.P. 01/21/202D 3D TSV
US9902714 35 7 HGNC:6307 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Quinoxaline derivatives useful as FGFR kinase modulators ASTEX THERAPEUTICS LTD 01/21/202D 3D TSV
US10246467 67 57 Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors Boehringer Ingelheim International GmbH 01/21/202D 3D TSV
US9902710 169 168 HGNC:8772 Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) EXONHIT THERAPEUTICS, SA; ALLERGAN, INC. 01/21/202D 3D TSV
US9896452 703 365 HGNC:4849 HGNC:4848 Substituted prolines/piperidines as orexin receptor antagonists EOLAS THERAPEUTICS, INC. 01/21/202D 3D TSV
US10251889 530 232 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 HGNC:12440 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors Array BioPharm Inc. 01/21/202D 3D TSV
US10253019 1854 609 HGNC:6192 HGNC:11584 HGNC:14552 Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. 01/21/202D 3D TSV
US9896447 46 46 HGNC:8031 TrkA kinase inhibitors, compositions and methods thereof Merck Sharp & Dohme Corp. 01/21/202D 3D TSV
US10238658 120 32 HGNC:4840 HGNC:11491 HGNC:11283 HGNC:4617 HGNC:4616 HGNC:6874 HGNC:6876 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors RESPIVERT LIMITED 12/30/192D 3D TSV
US10239843 681 620 HGNC:8605 HGNC:270 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG CANCER RESEARCH TECHNOLOGY LIMITED 12/30/192D 3D TSV
US10246425 16 16 HGNC:10593 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds Parion Sciences, Inc. 12/30/192D 3D TSV
US10246432 25 22 HGNC:4597 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators Heptares Therapeutics Limited 12/30/192D 3D TSV
US10239883 665 132 HGNC:6735 HGNC:4037 HGNC:1133 HGNC:11283 HGNC:6524 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors Merck Sharp & Dohme B.V. 12/30/192D 3D TSV
US10239868 43 43 HGNC:5302 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 12/30/192D 3D TSV
US10239840 22 22 Benzoazepine derivatives VIIV HEALTHCARE UK LIMITED 12/30/192D 3D TSV
US10238638 48 48 Benzothiazole and benzothiophene compounds Universite De Montreal; Bristol-Myers Squibb Company 12/30/192D 3D TSV
US10245267 2564 1057 HGNC:9829 Biaryl amide compounds as kinase inhibitors Novartis AG 12/30/192D 3D TSV
US10238743 98 49 HGNC:934 HGNC:933 C5-C6-fused tricyclic iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use TBA 12/30/192D 3D TSV
US10239870 462 190 HGNC:3023 Dopamine D3 receptor antagonists Indivior UK Limited 12/30/192D 3D TSV
US10239838 106 53 HGNC:4849 HGNC:4848 Heteroaryl orexin receptor antagonists Merck Sharp & Dohme Corp. 12/30/192D 3D TSV
US10246419 13 12 HGNC:7965 Liver X receptor (LXR) modulators RALEXAR THERAPEUTICS, INC. 12/30/192D 3D TSV
US10238633 584 357 HGNC:2528 Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C Boehringer Ingelheim International GmbH 12/30/192D 3D TSV
US10239835 142 141 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B CADENT THERAPEUTICS, INC. 12/30/192D 3D TSV
US10239887 97 75 HGNC:1953 Positive allosteric modulators of the muscarinic acetylcholine receptor M4 Vanderbilt University 12/30/192D 3D TSV
US10239881 26 25 HGNC:10020 RIPK2 inhibitors and method of treating cancer with same University Health Network 12/30/192D 3D TSV
US10239882 86 86 HGNC:8777 Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors DART NEUROSCIENCE (CAYMAN) LTD. 12/30/192D 3D TSV
US10239869 405 243 HGNC:10593 HGNC:10597 Sulfonamide compounds as voltage-gated sodium channel modulators LUPIN LIMITED 12/30/192D 3D TSV
US10239861 60 58 HGNC:8638 Therapeutic compounds and uses thereof GENETECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 12/30/192D 3D TSV
US10239876 170 169 HGNC:3020 Triaza-spirodecanones as DDR1 inhibitors Hoffman La-Roche Inc. 12/30/192D 3D TSV
US10246426 240 240 HGNC:1395 Triazole compounds as T-type calcium channel blockers IDORSIA PHARMACEUTICALS LTD 12/30/192D 3D TSV
US10245275 158 76 Triterpenoids with HIV maturation inhibitory activity VIIV HEALTHCARE UK (NO. 4) LIMITED 12/30/192D 3D TSV
US10246429 755 248 HGNC:934 HGNC:2529 HGNC:933 Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use AMGEN INC. 12/30/192D 3D TSV
US10227299 295 287 HGNC:1148 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones BAYER PHARMA AKTIENGESELLSCHAFT 12/27/192D 3D TSV
US10233156 57 57 HGNC:85 9-membered fused ring derivative SHIONOGI & CO., LTD. 12/27/192D 3D TSV
US10233178 24 8 HGNC:6833 HGNC:6834 HGNC:29079 Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use Oryzon Genomics, S.A. 12/27/192D 3D TSV
US10226452 45 45 HGNC:735 Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments The Regents of the University of California; Fondazione Istituto Italiano di Tecnologia 12/27/192D 3D TSV
US10233188 433 221 HGNC:1771 HGNC:1773 CDK2/4/6 inhibitors Pfizer Inc. 12/27/192D 3D TSV
US10227357 1107 650 HGNC:6342 Compounds and methods for kinase modulation, and indications therefor Plexxikon Inc. 12/27/192D 3D TSV
US10231967 323 159 HGNC:620 Compounds and their use as BACE inhibitors AstraZeneca AB 12/27/192D 3D TSV
US10227360 50 49 HGNC:19061 Compounds for use as GPR120 agonists Piramal Enterprises Limited 12/27/192D 3D TSV
US10227329 268 130 HGNC:9967 Compounds useful for treating disorders related to RET BLUEPRINT MEDICINES CORPORATION 12/27/192D 3D TSV
US10227314 13 13 HGNC:2501 Cystathionine-gamma-lyase (CSE) inhibitors SOVA PHARMACEUTICALS, INC. 12/27/192D 3D TSV
US10227373 6 6 Enantiomers of the 1′,6′-isomer of neplanocin A Auburn University 12/27/192D 3D TSV
US10227334 8 8 HGNC:3467 Estrogen receptor modulators and uses thereof Genentech, Inc. 12/27/192D 3D TSV
US10233187 49 47 HGNC:7967 Fused bicyclic compounds for the treatment of disease AKARNA THERAPEUTICS, LTD. 12/27/192D 3D TSV
US10233189 78 76 HGNC:9967 Fused pyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd. 12/27/192D 3D TSV
US10227310 6 6 HGNC:32311 Ghrelin 0-acyl transferase inhibitors Eli Lilly and Company 12/27/192D 3D TSV
US10227312 46 46 HGNC:12524 Glucosylceramide synthase inhibitors for the treatment of diseases BIOMARIN PHARMACEUTICAL INC. 12/27/192D 3D TSV
US10227342 400 99 HGNC:3236 Heteroaryl compounds for kinase inhibition ARIAD PHARMACEUTICALS, INC. 12/27/192D 3D TSV
US10226449 595 337 HGNC:3594 Heterocyclic modulators of lipid synthesis and combinations thereof 3-V Biosciences, Inc. 12/27/192D 3D TSV
US10231957 21 21 HGNC:17071 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 12/27/192D 3D TSV
US10233190 160 157 HGNC:6059 IDO inhibitors NEWLINK GENETICS CORPORATION 12/27/192D 3D TSV
US10227341 146 145 HGNC:1133 Inhibiting agents for bruton's tyrosine kinase BIOGEN MA INC. 12/27/192D 3D TSV
US10227327 27 11 Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety Universitetet | Oslo 12/27/192D 3D TSV
US10227343 112 109 HGNC:4596 Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction Vanderbilt University 12/27/192D 3D TSV
US10233152 161 158 HGNC:29079 LSD1 inhibitors MIRATI THERAPEUTICS, INC. 12/27/192D 3D TSV
US10227331 1137 369 Metallo-β-lactamase inhibitors Merck Sharp & Dohme Corp. 12/27/192D 3D TSV
US10231963 110 39 HGNC:8156 Methods for treating depressive symptoms ALKERMES PHARMA IRELAND LIMITED 12/27/192D 3D TSV
US10227346 104 104 HGNC:10260 Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof Pfizer Inc. 12/27/192D 3D TSV
US10227350 167 129 HGNC:8980 Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. 12/27/192D 3D TSV
US10227336 32 16 HGNC:4849 HGNC:4848 Pyrazole orexin receptor antagonists Merck Sharp & Dohme Corp 12/27/192D 3D TSV
US10227295 48 24 HGNC:4852 HGNC:14064 Selective histone deactylase 6 inhibitors H. Lee Moffitt Cancer Center and Research Institute, Inc.; Board of Trustees of The University of Illinois 12/27/192D 3D TSV
US10226464 150 75 HGNC:7794 Small molecule NF-κB inhibitors ImmuneTarget, Inc. 12/27/192D 3D TSV
US10233173 647 642 Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators JANSSEN PHARMACEUTICA NV 12/27/192D 3D TSV
US10227338 181 136 HGNC:10593 HGNC:10597 Substituted benzenesulfonamides as sodium channel blockers Daewoong Pharmaceutical Co., Ltd. 12/27/192D 3D TSV
US10233160 150 75 HGNC:391 HGNC:10436 Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors Merck Patent GmbH 12/27/192D 3D TSV
US10233182 245 244 HGNC:3357 Substituted spirocyclic inhibitors of autotaxin X-Rx, Inc. 12/27/192D 3D TSV
US10227332 8 4 HGNC:2160 T-type calcium channel modulator and uses thereof UTI LIMITED PARTNERSHIP; THE UNIVERSITY OF MONTANA 12/27/192D 3D TSV
US10233177 25 25 TRPV1 vanilloid receptor antagonists with a bicyclic portion TBA 12/27/192D 3D TSV
US10227340 27 26 HGNC:17967 Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors Bristol-Myers Squibb Company 12/27/192D 3D TSV
US10227359 58 28 HGNC:13575 Tricyclic heterocycles as bet protein inhibitors Incyte Corporation 12/27/192D 3D TSV
US9872852 297 292 HGNC:17635 Compounds useful as immunomodulators Bristol-Myers Squibb Company 12/19/192D 3D TSV
US9873693 331 307 Methods of treatment using pyridinonyl PDK1 inhibitors Sunesis Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc. 12/19/192D 3D TSV
US9873683 43 43 HGNC:8535 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD; KYUSHU UNIVERSITY 12/19/192D 3D TSV
US9873709 1144 774 HGNC:6190 HGNC:6192 Triazolopyridine compounds, compositions and methods of use thereof Genentech, Inc. 12/19/192D 3D TSV
US9867826 100 47 HGNC:391 Heterocycles as modulators of kinase activity Merck Patent GmbH 12/12/192D 3D TSV
US9868726 123 72 HGNC:6307 HGNC:8804 HGNC:9437 Pyridyl benzothiophenes as kinase inhibitors ALLERGAN, INC. 12/12/192D 3D TSV
US9868720 93 92 HGNC:6851 C-linked heterocycloaklyl substituted pyrimidines and their uses Genentech, Inc. 12/10/192D 3D TSV
US9868738 102 51 HGNC:934 HGNC:933 Diazine-fused amidines as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 12/10/192D 3D TSV
US9868744 23 19 HGNC:3020 Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. 12/10/192D 3D TSV
US9868729 216 214 HGNC:11491 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. 12/10/192D 3D TSV
US9867833 197 185 HGNC:6871 Serine/threonine kinase inhibitors GENENTECH, INC. 12/10/192D 3D TSV
US9868748 113 110 HGNC:10260 Thiazolopyrrolidine inhibitors of ROR- γ Vitae Pharmaceuticals, Inc. 12/10/192D 3D TSV
US9862688 47 7 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:76 HGNC:12440 Hydrophobically tagged janus kinase inhibitors and uses thereof Dana-Farber Cancer Institute, Inc. 12/03/192D 3D TSV
US9862730 405 393 HGNC:3540 Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation Bristol-Myers Squibb Company; Universite De Montreal 12/03/192D 3D TSV
US9861612 9 7 HGNC:10260 Indolyl-containing RORγt inhibitors ORCA PHARMACEUTICALS LIMITED 12/03/192D 3D TSV
US9862726 40 20 HGNC:8154 HGNC:8156 Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans Purdue Pharma L.P. 12/03/192D 3D TSV
US9862679 189 58 Potent and selective inhibitors of monoamine transporters; method of making; and use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH 12/03/192D 3D TSV
US9862711 91 13 HGNC:8978 HGNC:8984 HGNC:8975 HGNC:3942 HGNC:8974 HGNC:8977 HGNC:8976 Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors NOVARTIS AG 12/03/192D 3D TSV
US9862721 13 13 HGNC:3357 Tetrahydrocarboline derivative ONO PHARMACEUTICAL CO., LTD. 12/03/192D 3D TSV
US9862707 103 83 HGNC:8031 TrkA kinase inhibitors, compositions and methods thereof Merck Sharp & Dohme Corp. 12/03/192D 3D TSV
US9856252 107 106 HGNC:10894 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase Cancer Therapeutics CRC Pty Ltd 11/21/192D 3D TSV
US9855269 345 340 HGNC:6866 Aminoquinazoline and pyridopyrimidine derivatives Genentech, Inc. 11/21/192D 3D TSV
US9856239 42 38 HGNC:17989 Carboxylic acid compound, method for preparation thereof, and use thereof InventisBio Shanghai Ltd. 11/21/192D 3D TSV
US9856263 41 39 HGNC:3020 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. 11/21/192D 3D TSV
US9856220 125 124 HGNC:8772 Inhibitor compounds of phosphodiesterase type 10A AbbVie Deutschland GmbH & Co. KG; AbbVie Inc. 11/21/192D 3D TSV
US9856257 68 68 HGNC:16672 Pyrazolonaphthyridinone derivatives as MetAP2 inhibitors (methionine aminopeptidase type-2) SANOFI 11/21/192D 3D TSV
US9856274 42 42 HGNC:8772 Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors Sunovion Pharmaceuticals Inc. 11/21/192D 3D TSV
US9856250 58 57 HGNC:1395 Substituted tropane derivatives TOA EIYO LTD. 11/21/192D 3D TSV
US9855229 11 11 HGNC:10260 Treatment of respiratory disorders using ROR-gamma inhibitors GLENMARK PHARMACEUTICALS S.A. 11/21/192D 3D TSV
US9849138 10 5 1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties The Regents of the University of Michigan 11/14/192D 3D TSV
US9850203 128 122 HGNC:3357 Autotaxin inhibitor compounds PHARMAKEA, INC. 11/14/192D 3D TSV
US9850225 378 375 HGNC:17635 Compounds useful as immunomodulators Bristol-Myers Squibb Company 11/14/192D 3D TSV
US9845313 167 151 HGNC:10597 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED 11/14/192D 3D TSV
US9850245 24 21 HGNC:6255 Inhibitors of the renal outer medullary potassium channel Merck Sharp & Dohme Corp. 11/14/192D 3D TSV
US9845310 772 485 HGNC:339 Intermediates for preparing triazole agonists of the APJ receptor AMGEN INC. 11/14/192D 3D TSV
US9845308 66 62 HGNC:10260 Isoindoline inhibitors of ROR-gamma Vitae Pharmaceuticals, Inc. 11/14/192D 3D TSV
US9844553 19 10 HGNC:2592 HGNC:2591 Pyrazolopyridyl compounds as aldosterone synthase inhibitors Merck Sharp & Dohme Corp. 11/14/192D 3D TSV
US9844535 28 27 HGNC:6080 SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors Indiana University Research and Technology Corporation 11/14/192D 3D TSV
US9845333 164 47 HGNC:4848 Substituted 2-azabicycles and their use as orexin receptor modulators TBA 11/14/192D 3D TSV
US9850258 152 43 HGNC:6192 HGNC:1133 Substituted tetrahydrocarbazole and carbazole carboxamide compounds Bristol-Myers Squibb Company 11/14/192D 3D TSV
US9850277 402 207 Therapeutically active compositions and their methods of use AGIOS PHARMACEUTICALS, INC. 11/14/192D 3D TSV
US9850257 26 13 Tricyclic heterocycles as BET protein inhibitors Incyte Corporation; Incyte Holdings Corporation 11/14/192D 3D TSV
US9840503 33 10 HGNC:7027 HGNC:12446 Heterocyclic compounds and uses thereof Incyte Corporation 10/31/192D 3D TSV
US9840501 242 121 Morpholin-pyridine derivatives Hoffmann-La Roche Inc. 10/31/192D 3D TSV
US9840508 90 18 HGNC:11526 HGNC:11527 HGNC:11528 N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders OGED SA 10/31/192D 3D TSV
US9840498 95 32 HGNC:8978 HGNC:8975 HGNC:8977 Substituted quinazolin-4-one derivatives Novartis AG 10/31/192D 3D TSV
US9834554 41 41 HGNC:1133 BTK inhibitors Merck Sharp & Dohme Corp. 10/28/192D 3D TSV
US9834513 249 125 HGNC:6371 HGNC:6357 Benzylamine derivatives Kalvista Pharmceuticals Limited 10/28/192D 3D TSV
US9834543 16 12 HGNC:10597 Indazoles and use thereof Purdue Pharma L.P. 10/28/192D 3D TSV
US9833448 14 14 HGNC:16709 Piperidinone carboxamide azaindane CGRP receptor antagonists Merck Sharp & Dohme Corp. 10/28/192D 3D TSV
US9834548 407 129 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Pyridazine compounds as JAK inhibitors Portola Pharmaceuticals, Inc. 10/28/192D 3D TSV
US9834551 220 109 HGNC:6193 HGNC:6171 Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors ARRIEN PHARMACEUTICALS LLC 10/28/192D 3D TSV
US9834564 209 209 HGNC:8772 Substituted quinolines as PDE-10 inhibitors Sunovion Pharmaceuticals Inc. 10/28/192D 3D TSV
US9833457 26 13 HGNC:8783 Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors vTv Therapeutics LLC 10/28/192D 3D TSV
US9834565 58 29 Tricyclic heterocycles as bet protein inhibitors Incyte Corporation 10/28/192D 3D TSV
US10221182 98 19 HGNC:4586 HGNC:4585 HGNC:6251 HGNC:2625 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists RUGEN HOLDINGS (CAYMAN) LIMITED 10/27/192D 3D TSV
US10221172 65 64 HGNC:4596 Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction Vanderbilt University 10/27/192D 3D TSV
US10221173 451 159 HGNC:6251 HGNC:3467 Chemical compounds AstraZeneca AB 10/27/192D 3D TSV
US10221177 261 248 HGNC:497 Inhibiting the transient receptor potential A1 ion channel Hydra Biosciences, Inc. 10/27/192D 3D TSV
US10221163 1497 492 Metallo-beta-lactamase inhibitors Merck Sharp & Dohme Corp. 10/27/192D 3D TSV
US10221174 46 22 HGNC:6943 HGNC:990 N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN 10/27/192D 3D TSV
US10221197 528 147 HGNC:8978 HGNC:8980 HGNC:8977 Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. 10/27/192D 3D TSV
US10221178 83 82 HGNC:8977 Purine inhibitors of human phosphatidylinositol 3-kinase delta Merck Sharp & Dohme Corp. 10/27/192D 3D TSV
US10221195 46 44 HGNC:438 Pyridine compounds Daiichi Sankyo Company, Limited; Sanford Burnham Prebys Medical Discovery Institute 10/27/192D 3D TSV
USRE47267 31 25 HGNC:6027 Pyridinecarboxamides as CXCR2 modulators Syntrix Biosystems, Inc. 10/27/192D 3D TSV
US10221175 42 42 HGNC:1950 Substituted pyrrolo[3,4-e]indolizines, imidazo[1,2-a]pyrrolo[3,4-e]pyridines, pyrrolo[3,4-e][1,2,4]triazolo[1,5-a]pyridines and pyrrolo[3,4-e][1,2,4]triazolo[4,3-a]pyridines as positive allosteric modulators of muscarinic acetylcholine receptor M1 Vanderbilt University 10/27/192D 3D TSV
US9828368 146 64 HGNC:4849 Oxazole orexin receptor antagonists Merck Sharp & Dohme Corp. 10/24/192D 3D TSV
US9828396 92 92 HGNC:2771 Alkyne compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 10/22/192D 3D TSV
US9828348 10 10 HGNC:10597 Benzimidazole derivatives and use thereof Purdue Pharma L.P. 10/22/192D 3D TSV
US9828339 224 224 HGNC:1952 Biphenyl derivatives and methods for preparing same DONG-A ST CO., LTD 10/22/192D 3D TSV
US9828343 199 93 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 10/22/192D 3D TSV
US9828369 167 166 HGNC:16940 Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 Merck Sharpe & Dohme Corp. 10/22/192D 3D TSV
US9828378 257 69 HGNC:8978 HGNC:8972 HGNC:8975 HGNC:8977 Kinase inhibitors and methods of use Intellikine LLC 10/22/192D 3D TSV
US9828374 94 47 Substituted pyrazino[2,2-a]isoquinoline derivatives Hoffmann-La Roche Inc. 10/22/192D 3D TSV
US9828381 88 88 Substituted pyrazolopyrimidines and method of use AbbVie Deutschland GmbH & Co. KG; AbbVie Inc. 10/22/192D 3D TSV
US10214477 210 56 HGNC:6833 HGNC:6834 HGNC:29079 (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors Oryzon Genomics S.A. 10/20/192D 3D TSV
US10214524 20 19 2-heteroaryl carboxamides BAYER INTELLECTUAL PROPERTY GMBH 10/20/192D 3D TSV
US10214516 14 14 5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO.5) LIMITED 10/20/192D 3D TSV
US10214478 11 11 Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof TBA 10/20/192D 3D TSV
US10214545 36 18 Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders BAYER PHARMA AKTIENGESELLSCHAFT 10/20/192D 3D TSV
US10214509 35 18 HGNC:10593 HGNC:10597 Amino-substituted heterocyclic derivatives as sodium channel inhibitors Almirall, S.A. 10/20/192D 3D TSV
US10214536 76 76 HGNC:11584 Amlexanox analogs THE REGENTS OF THE UNIVERSITY OF MICHIGAN 10/20/192D 3D TSV
US9822124 255 85 HGNC:19310 HGNC:8987 Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors Incyte Corporation 10/20/192D 3D TSV
US10214537 824 774 HGNC:8977 Bicyclic heteroaryl amine compounds Bristol-Myers Squibb Company 10/20/192D 3D TSV
US10214528 152 37 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 10/20/192D 3D TSV
US10214546 213 174 HGNC:1133 Btk inhibitors Merck Sharp & Dohme Corp. 10/20/192D 3D TSV
US10214507 138 137 HGNC:8846 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators Reset Therapeutics, Inc. 10/20/192D 3D TSV
US10220048 100 97 HGNC:9665 Compositions and methods for treating ocular diseases AERPIO THERAPEUTICS, INC. 10/20/192D 3D TSV
US10213407 9 9 Compounds and methods for inhibiting production of trimethylamine THE PROCTER & GAMBLE COMPANY; THE CLEVELAND CLINIC FOUNDATION 10/20/192D 3D TSV
US10220040 9 9 Compounds, compositions and methods useful for cholesterol mobilization Cerenis Therapeutics Holding SA 10/20/192D 3D TSV
US9822074 99 94 HGNC:7045 Dihydropyridinone MGAT2 inhibitors Bristol-Myers Squibb Company 10/20/192D 3D TSV
US10214512 386 227 HGNC:3529 HGNC:6357 Factor XIA inhibitors Merck Sharp & Dohme Corp. 10/20/192D 3D TSV
US10214492 511 238 HGNC:10924 HGNC:10922 Heterocyclic inhibitors of MCT4 Vettore, LLC 10/20/192D 3D TSV
US10214535 32 16 HGNC:4849 HGNC:4848 Hydroxmethyl piperidine orexin receptor antagonists Merck Sharp & Dohme Corp. 10/20/192D 3D TSV
US10214544 155 154 HGNC:3540 Imidazopyridazine and imidazothiadiazole compounds Universite De Montreal 10/20/192D 3D TSV
US9822068 26 13 HGNC:3553 Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments The Regents of the University of California; Fondazione Istituto Italiano di Technologia 10/20/192D 3D TSV
US10221129 293 288 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO.5) LIMITED 10/20/192D 3D TSV
US9822103 94 92 HGNC:3527 Inhibitors of lysine methyl transferase Bristol-Myers Squibb Company 10/20/192D 3D TSV
US10221161 192 94 HGNC:6371 HGNC:6357 Inhibitors of plasma kallikrein Kalvista Pharmaceuticals Limited 10/20/192D 3D TSV
US10221160 12 4 HGNC:2637 HGNC:2623 HGNC:2621 Metalloenzyme inhibitor compounds Mycovia Pharmaceuticals, Inc. 10/20/192D 3D TSV
US9820989 119 88 HGNC:6307 HGNC:8804 Method of treating conditions with kinase inhibitors ALLERGAN, INC. 10/20/192D 3D TSV
US10214533 23 7 HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders OGEDA SA 10/20/192D 3D TSV
US10213421 10 10 HGNC:1604 Pharmaceutical formulations comprising CCR3 antagonists Alkahest, Inc. 10/20/192D 3D TSV
US10214519 354 327 HGNC:8980 Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. 10/20/192D 3D TSV
US9822120 64 32 HGNC:1133 Protein kinase inhibitors Pharmascience Inc. 10/20/192D 3D TSV
US10214518 8 6 HGNC:9602 Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto Arena Pharmaceuticals, Inc. 10/20/192D 3D TSV
US10221156 6 6 Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO.5) LIMITED 10/20/192D 3D TSV
US10214511 56 3 HGNC:11283 HGNC:11584 HGNC:14552 HGNC:17967 HGNC:12434 HGNC:6735 HGNC:2451 HGNC:5465 HGNC:4617 HGNC:2459 HGNC:6112 HGNC:2457 HGNC:3765 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:6171 HGNC:11390 HGNC:12440 HGNC:1079 HGNC:1133 HGNC:1771 HGNC:6860 HGNC:11719 HGNC:7972 HGNC:1774 HGNC:6524 HGNC:1775 Quinazolines as potassium ion channel inhibitors Bristol-Myers Squibb Company 10/20/192D 3D TSV
US10213433 373 370 HGNC:990 Solid dispersions containing an apoptosis-inducing agent AbbVie Inc. 10/20/192D 3D TSV
US10214534 44 44 Substituted 2-phenyl (AZA)benzofuran compounds for the treatment of hepatitis C Bristol-Myers Squibb Company 10/20/192D 3D TSV
US10213416 11 11 HGNC:735 Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments The Regents of the University of Chicago; Fondazione Istituto Italiano di Technologia 10/20/192D 3D TSV
US10213427 107 107 HGNC:3690 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 Incyte Corporation; Incyte Holdings Corporation 10/20/192D 3D TSV
US9822102 357 143 HGNC:6371 HGNC:3529 Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders BAYER PHARMA AKTIENGESELLSCHAFT 10/20/192D 3D TSV
US10221142 124 118 HGNC:10260 Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 10/20/192D 3D TSV
US10214515 36 9 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Substituted pyrazoles as inhibitors of fibroblast growth factor receptor Zhejiang Hisun Pharmaceutical Co., Ltd. 10/20/192D 3D TSV
US10221146 424 411 HGNC:10260 Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease Lycera Corporation; Merck Sharp & Dohme Corp. 10/20/192D 3D TSV
US10221162 788 507 HGNC:339 Triazole agonists of the APJ receptor AMGEN INC. 10/20/192D 3D TSV
US10214527 94 65 HGNC:7218 Triazolopyridine inhibitors of myeloperoxidase Bristol-Myers Squibb Company 10/20/192D 3D TSV
US10214530 118 57 HGNC:12008 HGNC:20692 Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN 10/20/192D 3D TSV
US9815850 266 255 Compounds, compositions and methods Denali Therapeutics Inc. 10/14/192D 3D TSV
US9815836 74 33 HGNC:17967 Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof Merck Patent GmbH 10/14/192D 3D TSV
US9815840 24 24 HGNC:7029 Protein kinase inhibitor containing pyrrolopyridazine derivative The Asan Foundation 10/14/192D 3D TSV
US9815842 127 126 HGNC:6819 Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors Novartis AG 10/14/192D 3D TSV
US9815861 12 12 HGNC:7056 Selective glycosidase inhibitors and uses thereof Alectos Therapeutics, Inc.; Merck Sharp & Dohme Corp. 10/14/192D 3D TSV
US9815846 228 227 HGNC:8031 TrkA kinase inhibitors, compositions and methods thereof Merck Sharp & Dohme Corp. 10/14/192D 3D TSV
US9815832 184 92 HGNC:8781 HGNC:8783 Azabenzimidazole compounds Pfizer Inc. 10/13/192D 3D TSV
US9815790 48 23 HGNC:2160 HGNC:2159 Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists Janssen Pharmaceutica NV 10/13/192D 3D TSV
US9815819 87 76 HGNC:2771 Complement pathway modulators and uses thereof NOVARTIS AG 10/13/192D 3D TSV
US9814715 14 7 HGNC:7966 HGNC:7965 Liver X receptor modulators Vitae Pharamceuticals, Inc. 10/13/192D 3D TSV
US9815796 1267 689 HGNC:8777 Pyrimidone carboxamide compounds as PDE2 inhibitors Merck Sharp & Dohme Corp.; MSD R & D (China) Co. LTD. 10/13/192D 3D TSV
US9815834 91 91 HGNC:3688 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. 10/13/192D 3D TSV
US9815820 30 7 HGNC:10251 HGNC:10252 Rho kinase inhibitors Kadmon Corporation, LLC 10/13/192D 3D TSV
US9814704 167 166 HGNC:6850 Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors The University of Rochester 10/13/192D 3D TSV
US9809582 68 24 HGNC:8781 HGNC:1952 Aminoester derivatives CHIESI FARMACEUTICI S.p.A. 10/07/192D 3D TSV
US9809568 7 7 HGNC:18618 Compounds inhibiting leucine-rich repeat kinase enzyme activity Merck Sharp & Dohme Corp. 10/07/192D 3D TSV
US9809572 16 1 HGNC:427 Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds Suzhou Zelgen Biopharmaceuticals Co., Ltd. 10/07/192D 3D TSV
US9808445 32 30 HGNC:3551 Factor IXa inhibitors Merck Sharp & Dohme Corp.; Mochida Pharmaceutical Co., Ltd. 10/07/192D 3D TSV
US9809545 25 25 HGNC:3551 Factor XIa inhibitors Merck Sharp & Dohme Corp. 10/07/192D 3D TSV
US9809574 248 248 HGNC:990 Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER; VERNALIS (R&D) LTD 10/07/192D 3D TSV
US9809583 31 31 Oxazolidine-based compound and selective androgen receptor agonist comprising same DONG-A ST CO., LTD. 10/07/192D 3D TSV
US9809561 424 422 HGNC:10260 Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease MERCK SHARP & DOHME CORP.; LYCERA CORPORATION 10/07/192D 3D TSV
US9802907 47 44 HGNC:12805 2-aryl selenazole compound and pharmaceutical composition thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. 10/01/192D 3D TSV
US9802947 18 9 HGNC:2536 HGNC:2545 3-oxo-tetrahydro-furo[3,2-b]pyrrol-4(5H)-yl) derivatives II GRÜNENTHAL GMBH 10/01/192D 3D TSV
US9802924 43 43 HGNC:5302 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 10/01/192D 3D TSV
US9802944 68 34 HGNC:10555 Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors Hoffmann-La Roche Inc. 10/01/192D 3D TSV
US9801889 200 37 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 10/01/192D 3D TSV
US9802928 48 24 HGNC:934 HGNC:933 C-6 spirocarbocyclic iminothiadiazine dioxides as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 10/01/192D 3D TSV
US9802960 484 476 HGNC:8974 Heteroaryls and uses thereof Millennium Pharmaceuticals, Inc. 10/01/192D 3D TSV
US9802945 23 23 HGNC:4076 Imidazopyridazine derivatives as modulators of the GABAA receptor activity Pfizer Limited 10/01/192D 3D TSV
US9802915 262 215 HGNC:1133 Indole carboxamide compounds Bristol-Myers Squibb Company 10/01/192D 3D TSV
US9802920 20 20 HGNC:1133 Inhibitors of bruton's tyrosine kinase Hoffman-La Roche Inc.; Chugai Pharamceutical Co. 10/01/192D 3D TSV
US9802904 64 62 Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof The United States of America, as represented by the Secretary, Department of Health and Human Services; University of Delaware 10/01/192D 3D TSV
US9802939 77 77 HGNC:3529 Macrocycles as factor XIa inhibitors Bristol-Myers Squibb Company 10/01/192D 3D TSV
US9802918 324 107 HGNC:19310 HGNC:8987 Pyridineamine compounds useful as Pim kinase inhibitors Incyte Corporation 10/01/192D 3D TSV
US9801872 35 34 HGNC:1133 Pyridinyl and fused pyridinyl triazolone derivatives Takeda Pharmaceutical Company Limited 10/01/192D 3D TSV
US9801888 129 129 HGNC:3942 Pyrimidine compounds as mTOR and PI3K inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY 10/01/192D 3D TSV
US9801878 34 32 HGNC:8772 Quinoline derivatives as PDE10A enzyme inhibitors H. Lundbeck A/S 10/01/192D 3D TSV
US9796719 321 219 HGNC:3357 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV 09/24/192D 3D TSV
US9796741 168 167 HGNC:2771 Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 09/23/192D 3D TSV
US9796664 27 11 HGNC:4852 HGNC:4854 HGNC:4853 Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors BIOMARIN PHARMACEUTICAL INC. 09/23/192D 3D TSV
US9796729 36 33 HGNC:2843 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE LLC 09/23/192D 3D TSV
US9796710 47 44 HGNC:10260 Dihydropyrrolopyridine inhibitors of ROR-gamma Vitae Pharmaceuticals, Inc. 09/23/192D 3D TSV
US9796702 52 23 HGNC:2592 HGNC:2591 Dihydroquinoline pyrazolyl compounds Hoffmann-La Roche Inc. 09/23/192D 3D TSV
US9796700 349 344 HGNC:6877 ERK inhibitors and uses thereof Celgene CAR LLC 09/23/192D 3D TSV
US9796680 41 31 HGNC:4177 Glucocerebrosidase modulators and uses thereof Alectos Therapeutics Inc. 09/23/192D 3D TSV
US9796720 31 31 HGNC:7978 Imidazole-derived modulators of the glucocorticoid receptor Bristol-Myers Squibb Company 09/23/192D 3D TSV
US9796706 505 173 HGNC:6881 HGNC:6872 HGNC:6886 Inhibitors of Jun N-terminal kinase IMAGO PHARMACEUTICALS, INC. 09/23/192D 3D TSV
US9796672 170 93 HGNC:8157 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. 09/23/192D 3D TSV
US9796742 135 61 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 Kinase inhibitors Respivert Limited; Topivert Pharma Limited 09/23/192D 3D TSV
US9795611 60 59 HGNC:8031 Method of treatment using substituted imidazo[1,2b]pyridazine compounds Array BioPharma, Inc. 09/23/192D 3D TSV
US9796723 60 60 HGNC:8031 Method of treatment using substituted imidazo[1,2b]pyridazine compounds Array BioPharma, Inc. 09/23/192D 3D TSV
US9796707 36 36 HGNC:11305 Piperazine derivatives for treating disorders The University of Nottingham; NewSouth Innovations PTY Limited 09/23/192D 3D TSV
US9795602 9 9 HGNC:9213 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use GILEAD SCIENCES, INC. 09/23/192D 3D TSV
US9795608 15 15 HGNC:1133 Protein kinase inhibitors PHARMASCIENCE, INC. 09/23/192D 3D TSV
US9796725 125 122 HGNC:30661 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme Millennium Pharmaceuticals, Inc. 09/23/192D 3D TSV
US9796732 42 42 HGNC:3942 Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. 09/23/192D 3D TSV
US9796708 1363 1352 HGNC:1780 Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors AbbVie Inc. 09/23/192D 3D TSV
US9795606 35 35 HGNC:7027 Pyrrolopyrimidine compounds for the treatment of cancer The University of North Carolina at Chapel Hill 09/23/192D 3D TSV
US9796687 18 18 HGNC:8791 S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS 09/23/192D 3D TSV
US9796716 127 124 HGNC:1133 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. 09/23/192D 3D TSV
US9796724 517 232 HGNC:8031 HGNC:12440 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors Array BioPharma, Inc. 09/23/192D 3D TSV
US9796704 1540 275 HGNC:3763 HGNC:3430 HGNC:6307 HGNC:3386 HGNC:3395 HGNC:3236 Substituted quinazolines as receptor-type kinase inhibitors SYMPHONY EVOLUTION, INC. 09/23/192D 3D TSV
US10208016 23 23 HGNC:4524 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors TAKEDA PHARMACEUTICAL COMPANY LIMITED 09/21/192D 3D TSV
US10208024 246 83 HGNC:3690 HGNC:3689 HGNC:3688 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases Array BioPharma Inc. 09/21/192D 3D TSV
US10208044 3 3 HGNC:85 ACC inhibitors and uses thereof GILEAD APOLLO, LLC 09/21/192D 3D TSV
US10208011 50 25 HGNC:4485 Benzothiophene estrogen receptor modulators G1 Therapeutics, Inc. 09/21/192D 3D TSV
US10208081 137 133 HGNC:7967 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof Enanta Pharmaceuticals, Inc. 09/21/192D 3D TSV
US10206907 633 322 Compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV 09/21/192D 3D TSV
US10208056 240 97 HGNC:19682 HGNC:1779 Condensed tricyclic compounds as protein kinase inhibitors FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO) 09/21/192D 3D TSV
US10208000 19 19 Eis inhibitors University of Kentucky Research Foundation 09/21/192D 3D TSV
US10208040 34 11 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Fused imidazo-piperidine JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC 09/21/192D 3D TSV
US10208019 434 246 HGNC:4324 GLP-1 receptor agonists and uses thereof Pfizer Inc. 09/21/192D 3D TSV
US10208023 23 7 HGNC:10597 Heterocyclic inhibitors of the sodium channel TBA 09/21/192D 3D TSV
US10208039 147 146 HGNC:17071 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 09/21/192D 3D TSV
US10208066 156 68 HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 Imidazopyridazine compounds and their use HUTCHISON MEDIPHARMA LIMITED 09/21/192D 3D TSV
US10208060 10 10 HGNC:1232 Inhibitors of HIF prolyl hydroxylase Merck Sharp & Dohme Corp. 09/21/192D 3D TSV
US10207999 226 119 HGNC:29079 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. 09/21/192D 3D TSV
US10208064 36 36 HGNC:6255 Inhibitors of the renal outer medullary potassium channel WuXi AppTec (Shanghai) Co Ltd 09/21/192D 3D TSV
US10207991 170 93 HGNC:8157 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. 09/21/192D 3D TSV
US10208068 46 46 HGNC:3529 Macrocycles as factor XIa inhibitors Bristol-Myers Squibb Company 09/21/192D 3D TSV
US10208043 31 31 Methods for inhibiting fascin Cornell University; Novita Pharmaceuticals, Inc. 09/21/192D 3D TSV
US10208027 4 1 HGNC:882 Processes for preparing ATR inhibitors Vertex Pharmaceuticals Incorporated 09/21/192D 3D TSV
US10208020 126 62 HGNC:17432 HGNC:1936 Substituted amino triazoles useful as human chitinase inhibitors OncoArendi Therapeutics S.A. 09/21/192D 3D TSV
US10208021 21 21 HGNC:3529 Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors Bristol-Myers Squibb Company 09/21/192D 3D TSV
US10208047 36 35 HGNC:1133 Tertiary alcohol imidazopyrazine BTK inhibitors Merck Sharp & Dohme Corp. 09/21/192D 3D TSV
US10206931 611 311 HGNC:2348 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 09/21/192D 3D TSV
US10208071 189 187 HGNC:3827 Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases ALLERGAN, INC. 09/21/192D 3D TSV
US9789094 21 21 HGNC:6059 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Incyte Holdings Corporation; Incyte Corporation 09/09/192D 3D TSV
US9790230 212 106 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives Hoffmann-La Roche Inc. 09/09/192D 3D TSV
US9790229 360 356 HGNC:1133 Bruton's tyrosine kinase inhibitors Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. 09/09/192D 3D TSV
US9790233 21 19 HGNC:5154 Compositions and methods of modulating 15-PGDH activity Case Western Reserve University; Board of Regents of the University of Texas System; University of Kentucky Research Foundation 09/09/192D 3D TSV
US9789116 96 91 HGNC:5154 Compositions and methods of modulating short-chain dehydrogenase activity Case Western Reserve University; Board of Regents of the University of Texas System 09/09/192D 3D TSV
US9789100 132 45 Compounds as rearranged during transfection (RET) inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 09/09/192D 3D TSV
US9789110 55 55 HGNC:16940 Diacylglycerol acyltransferase 2 inhibitors Pfizer Inc. 09/09/192D 3D TSV
US9790212 110 72 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED 09/09/192D 3D TSV
US9790221 574 287 HGNC:17967 Heteroaryl compounds as IRAK inhibitors and uses thereof Merck Patent GmbH 09/09/192D 3D TSV
US9790228 640 194 HGNC:8979 HGNC:8978 HGNC:8972 HGNC:8977 Heterocyclic kinase inhibitors Intellikine LLC 09/09/192D 3D TSV
US9790203 25 25 HGNC:8772 Inhibitor compounds of phosphodiesterase type 10A ABBVIE INC.; ABBVIE DEUTSCHLAND GMBH & CO. KG 09/09/192D 3D TSV
US9790174 318 118 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 Kinase inhibitors Respivert Limited; Topivert Pharma Limited 09/09/192D 3D TSV
US9790209 47 17 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 Kinase inhibitors Respivert Limited; Topivert Pharma Limited 09/09/192D 3D TSV
US9790196 12 4 HGNC:6833 HGNC:6834 HGNC:29079 Lysine demethylase inhibitors for diseases and disorders associated with Flaviviridae ORYZON GENOMICS S.A. 09/09/192D 3D TSV
US9790235 133 130 HGNC:6887 MK2 inhibitors and uses thereof Celgene CAR LLC 09/09/192D 3D TSV
US9791447 30 10 HGNC:17927 HGNC:30402 HGNC:23116 Methods of identifying SENP1 inhibitors City of Hope 09/09/192D 3D TSV
US9790201 119 113 HGNC:4524 Piperidine and azepine derivatives as prokineticin receptor modulators Takeda Pharmaceutical Company Limited 09/09/192D 3D TSV
US9790180 126 41 HGNC:4852 HGNC:4854 HGNC:4853 Piperidine derivatives as HDAC1/2 inhibitors REGENACY PHARMACEUTICALS, LLC 09/09/192D 3D TSV
US9790217 174 85 HGNC:2592 HGNC:2591 Pyridinyloxy- and phenyloxy-pyrazolyl compounds Hoffmann-La Roche Inc. 09/09/192D 3D TSV
US9789082 100 20 HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 Somatostatin receptor subtype 4 (SSTR4) agonists Centrexion Therapeutics Corporation 09/09/192D 3D TSV
US9790198 102 98 HGNC:4498 Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes Janssen Pharmaceutica NV 09/09/192D 3D TSV
US9790220 49 25 HGNC:4849 HGNC:4848 Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists Takeda Pharmaceutical Company Limited 09/09/192D 3D TSV
US9790158 24 12 HGNC:14063 HGNC:13315 Substituted tropolone derivatives and methods of use UNIVERSITY OF CONNECTICUT 09/09/192D 3D TSV
US10202412 19 16 β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections Atea Pharmaceuticals, Inc. 09/02/192D 3D TSV
US10202369 883 393 HGNC:2596 HGNC:2637 HGNC:2625 HGNC:8534 HGNC:2622 HGNC:2623 1,3-thiazol-2-yl substituted benzamides Bayer Aktiengesellschaft 09/02/192D 3D TSV
US10202365 79 39 HGNC:9967 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors BLUEPRINT MEDICINES CORPORATION 09/02/192D 3D TSV
US10202411 20 15 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV IDENIX PHARMACEUTICALS LLC 09/02/192D 3D TSV
US10202377 207 115 HGNC:11772 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof Samumed, LLC 09/02/192D 3D TSV
US10202383 46 46 HGNC:3009 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Boehringer Ingelheim International GmbH 09/02/192D 3D TSV
US10202370 154 153 HGNC:6342 Benzimidazole derivatives as selective proteine kinase inhibitors AB SCIENCE 09/02/192D 3D TSV
US10202368 88 88 HGNC:23692 CXCR7 receptor modulators IDORSIA PHARMACEUTICALS LTD. 09/02/192D 3D TSV
US10202399 34 34 HGNC:2671 Dihydroxy aromatic heterocyclic compound Takeda Pharmaceutical Company Limited 09/02/192D 3D TSV
US10202388 53 43 HGNC:11708 HGNC:6059 Fused-ring compounds, pharmaceutical composition and uses thereof SHANGHAI DE NOVO PHARMATECH CO., LTD. 09/02/192D 3D TSV
US10202390 29 28 HGNC:6266 Heteroaryl substituted aminopyridine compounds Bristol-Myers Squibb Company 09/02/192D 3D TSV
US10202373 49 49 HGNC:8974 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. 09/02/192D 3D TSV
US10202367 71 62 Heterocyclic compounds and methods of use thereof The United States of America, as represented by the Secretary, Department of Health and Human Services; University of Kansas 09/02/192D 3D TSV
US10202381 147 145 HGNC:17071 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 09/02/192D 3D TSV
US10202418 29 20 HGNC:9958 HGNC:2529 Hydroxy-ethylene derivatives for the treatment of arthrosis MERCK PATENT GMBH 09/02/192D 3D TSV
US10202362 4 2 HGNC:2528 HGNC:6710 Inhibitors of leukotriene A4 hydrolase Celtaxsys, Inc. 09/02/192D 3D TSV
US10202350 187 81 HGNC:10924 HGNC:23357 MCT4 inhibitors for treating disease Vettore, LLC 09/02/192D 3D TSV
US10202403 19 18 Macrocyclic benzofuran compounds for the treatment of hepatitis C Bristol-Myers Squibb Company 09/02/192D 3D TSV
US10202375 36 26 N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors Redx Pharma PLC 09/02/192D 3D TSV
US10202371 151 19 HGNC:8978 HGNC:8975 HGNC:3942 HGNC:8977 HGNC:8976 Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors Novartis AG 09/02/192D 3D TSV
US10202404 128 127 Polycyclic pyridone derivative having integrase inhibitory activity SHIONOGI & CO., LTD. 09/02/192D 3D TSV
US10202389 125 120 HGNC:12469 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme Millennium Pharmaceuticals, Inc. 09/02/192D 3D TSV
US10202379 784 388 HGNC:11535 Substituted polycyclic carbamoyl pyridone derivative prodrug SHIONOGI & CO., LTD. 09/02/192D 3D TSV
US10202360 382 361 HGNC:13575 HGNC:2348 Therapeutic compounds CELGENE QUANTICEL RESEARCH, INC. 09/02/192D 3D TSV
US10202354 120 120 HGNC:13610 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 09/02/192D 3D TSV
US10202378 434 200 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 09/02/192D 3D TSV
US9783488 107 107 HGNC:14063 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI Foundation, Inc. 08/20/192D 3D TSV
US9783501 80 80 HGNC:10582 Substituted quinolines as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED 08/20/192D 3D TSV
US9783543 38 19 HGNC:7110 Aminoimidazopyridazines BAYER PHARMA AKTIENGESELLSCHAFT 08/19/192D 3D TSV
US9783530 84 40 HGNC:3529 HGNC:6357 Factor Xla inhibitors Merck Sharp & Dohme Corp. 08/19/192D 3D TSV
US9783573 132 66 HGNC:592 IAP antagonists Bristol-Myers Squibb Company 08/19/192D 3D TSV
US9783527 470 356 HGNC:10582 HGNC:10597 Indazole ureas and method of use AbbVie Inc. 08/19/192D 3D TSV
US9783556 68 22 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 Kinase inhibitors Respivert Limited; Topivert Pharma Limited 08/19/192D 3D TSV
US9783524 48 10 HGNC:427 HGNC:3236 Protein tyrosine kinase modulators and methods of use BETTA PHARMACEUTICALS CO., LTD. 08/19/192D 3D TSV
US9783551 11 9 HGNC:9642 Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease Glaceum Inc. 08/19/192D 3D TSV
US9783511 263 255 HGNC:10260 Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease Lycera Corporation; Merck Sharp & Dohme Corp. 08/18/192D 3D TSV
US9783500 109 18 HGNC:7872 HGNC:7873 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition Northwestern University 08/17/192D 3D TSV
US9783499 24 24 HGNC:7029 Quinoline derivatives and their applications Shenyang Pharmaceutical University 08/17/192D 3D TSV
US9782415 530 232 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors Array BioPharma, Inc. 08/17/192D 3D TSV
US9777004 61 33 Amino-substituted imidazopyridazines BAYER INTELLECTUAL PROPERTY GMBH 08/13/192D 3D TSV
US9777020 185 185 HGNC:8031 Furo-3-carboxamide derivatives and methods of use AbbVie Inc. 08/13/192D 3D TSV
US9777008 310 306 HGNC:29652 PRMT5 inhibitors and uses thereof Epizyme, Inc. 08/13/192D 3D TSV
US9777010 124 111 HGNC:9922 Substituted 4-phenylpiperidines, their preparation and use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 08/13/192D 3D TSV
US9777017 196 90 HGNC:6190 HGNC:6192 Tricyclic fused thiophene derivatives as JAK inhibitors Incyte Holdings Corporation; Incyte Corporation 08/13/192D 3D TSV
US9776995 524 366 HGNC:10593 HGNC:10597 Bicyclic sulfonamide compounds as sodium channel inhibitors Amgen Inc. 08/12/192D 3D TSV
US9776990 146 73 HGNC:13575 Isoindolone derivatives AbbVie Inc. 08/12/192D 3D TSV
US9777000 173 158 HGNC:8772 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. 08/12/192D 3D TSV
US9776991 211 206 HGNC:3402 Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase SANOFI 08/12/192D 3D TSV
US9777003 544 269 HGNC:13575 Tricyclic heterocycles as bet protein inhibitors Incyte Corporation 08/12/192D 3D TSV
US9775839 42 41 HGNC:11491 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors Merck Sharp & Dohme Corp. 08/11/192D 3D TSV
US9775844 440 109 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. 08/11/192D 3D TSV
US9776974 122 119 HGNC:29079 Inhibitors of lysine specific demethylase-1 Celgene Quanticel Research, Inc. 08/11/192D 3D TSV
US9776988 32 8 HGNC:6307 HGNC:3690 HGNC:3689 HGNC:3688 Pyrazolylbenzo[d]imidazole derivatives Celon Pharma S.A. 08/11/192D 3D TSV
US9771369 502 253 HGNC:6342 Compounds and methods for kinase modulation, and indications therefor Plexxikon Inc. 08/06/192D 3D TSV
US9771375 159 156 HGNC:6315 Indazole compounds useful as ketohexokinase inhibitors Janssen Pharmaceutica NV 08/06/192D 3D TSV
US9771353 39 14 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6874 Kinase inhibitors based upon N-alkyl pyrazoles TOPIVERT PHARMA LIMITED; RESPIVERT LIMITED 08/06/192D 3D TSV
US9771379 28 28 HGNC:933 N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides PFIZER INC. 08/06/192D 3D TSV
US9771376 56 51 HGNC:10593 HGNC:10597 N-substituted benzamides and methods of use thereof GENENTECH, INC.; XENON PHARMACEUTICALS INC. 08/06/192D 3D TSV
US9771359 37 33 HGNC:12716 Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II Medifron DBT Inc. 08/06/192D 3D TSV
US9771366 28 20 HGNC:10435 HGNC:10431 HGNC:10430 HGNC:10432 Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors PHOENIX MOLECULAR DESIGN 08/06/192D 3D TSV
US9771320 334 293 HGNC:10260 Carbocyclic sulfone RORγ modulators Bristol-Myers Squibb Company 08/05/192D 3D TSV
US9771329 122 119 HGNC:29079 Inhibitors of lysine specific demethylase-1 Celgene Quanticel Research, Inc. 08/05/192D 3D TSV
US9771316 35 17 HGNC:11063 Phenoxyalkylamine compound Osaka University; KNC Laboratories Co., Ltd. 08/02/192D 3D TSV
US9763922 595 308 HGNC:13575 HGNC:2348 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 07/30/192D 3D TSV
US9765057 34 14 HGNC:4849 HGNC:4848 3-ester-4 substituted orexin receptor antagonists Merck Sharp & Dohme Corp. 07/29/192D 3D TSV
US9765037 344 136 HGNC:4840 HGNC:11283 HGNC:76 Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases University of Washington Through its Center for Commercialization 07/29/192D 3D TSV
US9765038 62 23 HGNC:3236 Heteroaryl compounds and uses thereof Celgene CAR LLC 07/29/192D 3D TSV
US9765054 75 74 HGNC:14063 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI Foundation, Inc. 07/29/192D 3D TSV
US9765056 173 173 HGNC:990 Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER; VERNALIS (R&D) LTD 07/29/192D 3D TSV
US9765068 193 193 HGNC:10894 PRMT5 inhibitors and uses thereof Epizyme, Inc. 07/29/192D 3D TSV
US9765060 118 113 HGNC:8977 Phosphatidylinositol 3-kinase inhibitors GILEAD SCIENCES, INC. 07/29/192D 3D TSV
US9765029 40 37 HGNC:10597 Pyridine compounds as sodium channel blockers Purdue Pharma L.P. 07/29/192D 3D TSV
US9765058 20 19 HGNC:1148 Substituted benzylpyrazoles Bayer Pharma Aktiengesellschaft 07/29/192D 3D TSV
US9765070 81 39 HGNC:6371 HGNC:3529 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT 07/29/192D 3D TSV
US9765040 15 15 Therapeutic agent for pain Astellas Pharma Inc. 07/29/192D 3D TSV
US9765092 444 442 HGNC:12008 Tricyclic piperidine compounds ACTELION PHARMACEUTICALS LTD 07/29/192D 3D TSV
US9763957 206 201 HGNC:10548 Autotaxin inhibitors Novartis AG 07/26/192D 3D TSV
US9763952 568 263 HGNC:8975 HGNC:8977 Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives NOVARTIS AG 07/26/192D 3D TSV
US9765018 65 65 HGNC:6059 IDO inhibitors Bristol-Myers Squibb Company; Syngene International Limited; Bristol-Myers Squibb Company 07/26/192D 3D TSV
US9763943 43 43 HGNC:8031 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. 07/26/192D 3D TSV
US9758480 44 44 HGNC:3529 1-(cycloalkyl-carbonyl)proline derivative SUMITOMO DAINIPPON PHARMA CO., LTD. 07/22/192D 3D TSV
US9758508 11 11 HGNC:1133 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same CrystalGenomics, Inc. 07/22/192D 3D TSV
US9758505 35 35 HGNC:11708 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use iTeos Therapeutics 07/22/192D 3D TSV
US9758524 664 132 HGNC:6735 HGNC:4037 HGNC:1133 HGNC:11283 HGNC:6524 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors Merck Sharp & Dohme B.V. 07/22/192D 3D TSV
US10202344 88 67 HGNC:10597 Aryl substituted indoles and the use thereof Purdue Pharma L.P. 07/22/192D 3D TSV
US10201527 144 95 HGNC:4852 HGNC:4774 HGNC:13315 Benzimidazole derivatives: preparation and pharmaceutical applications MEI PHARMA, INC. 07/22/192D 3D TSV
US9758537 116 116 HGNC:2771 Compounds for treatment of complement mediated disorders Achillion Pharmaceuticals 07/22/192D 3D TSV
US9757383 30 15 HGNC:286 HGNC:1952 Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities Almirall, S.A. 07/22/192D 3D TSV
US10202340 49 17 HGNC:12524 Glucosylceramide synthase inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN 07/22/192D 3D TSV
US9758495 7 7 Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer Amgen Inc. 07/22/192D 3D TSV
US9757369 28 27 HGNC:4617 Heterocyclic GSK-3 allosteric modulators Consejo Superior de Investigaciones Cientificas (CSIC) 07/22/192D 3D TSV
US9758517 21 21 HGNC:17071 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 07/22/192D 3D TSV
US10202330 54 18 HGNC:6833 HGNC:6834 HGNC:29079 Lysine specific demethylase-1 inhibitors and their use ORYZON GENOMICS, SA 07/22/192D 3D TSV
US9757364 370 71 HGNC:6307 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Naphthyridine derivative compounds ASTEX THERAPEUTICS LTD 07/22/192D 3D TSV
US9758483 160 159 HGNC:10582 Pyridone amides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED 07/22/192D 3D TSV
US9758538 157 153 HGNC:8979 Pyrimidine derivatives PFIZER INC. 07/22/192D 3D TSV
US10201546 769 362 HGNC:10260 Quinolinyl modulators of RORγt Janssen Pharmaceutica NV 07/22/192D 3D TSV
US10201545 102 102 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. 07/22/192D 3D TSV
US10202339 353 350 Therapeutic compounds and compositions Agios Pharmaceuticals, Inc. 07/22/192D 3D TSV
US9758523 20 20 HGNC:29079 Triazolopyridines and triazolopyrazines as LSD1 inhibitors Incyte Corporation 07/22/192D 3D TSV
US9751886 33 10 HGNC:934 HGNC:933 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) Janssen Pharmaceutica NV 07/11/192D 3D TSV
US9751873 161 138 HGNC:10260 Aryl sultam derivatives as RORc modulators Genentech, Inc. 07/11/192D 3D TSV
US9751885 801 224 HGNC:6833 HGNC:6834 HGNC:29079 Cyclopropanamine compound and use thereof Takeda Pharmaceutical Company Limited 07/11/192D 3D TSV
US9751856 6 6 Ethynyl derivatives HOFFMANN-LA ROCHE INC. 07/11/192D 3D TSV
US9751854 484 477 HGNC:8974 Heteroaryls and uses thereof Millennium Pharmaceuticals, Inc. 07/11/192D 3D TSV
US9751888 236 58 HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. 07/11/192D 3D TSV
US9751881 118 115 HGNC:6255 Inhibitors of the renal outer medullary potassium channel Merck Sharp & Dohme Corp. 07/11/192D 3D TSV
US9751837 187 70 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 Kinase inhibitors RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED 07/11/192D 3D TSV
US9750744 68 47 HGNC:8031 Macrocyclic compounds as Trk kinase inhibitors Array BioPharma, Inc. 07/11/192D 3D TSV
US9750748 14 14 HGNC:2671 Pyridazinones as DAAO enzyme inhibitors Takeda Pharmaceutical Company Limited 07/11/192D 3D TSV
US9751832 42 21 HGNC:4852 HGNC:14064 Selective histone deactylase 6 inhibitors H. Lee Moffitt Cancer Center and Research Institute, Inc.; Board of Trustees of the University of Illinois 07/11/192D 3D TSV
US9751843 148 148 HGNC:2097 Substituted uracils and use thereof Bayer Pharma Aktiengesellschaft 07/11/192D 3D TSV
US9751850 11 11 HGNC:497 TRPA1 antagonists ABBVIE INC. 07/11/192D 3D TSV
US9744173 132 114 HGNC:933 HGNC:2625 2-amino 6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides Pfizer Inc. 07/05/192D 3D TSV
US9745284 120 59 HGNC:4849 HGNC:4848 2-pyridyloxy-4-ether orexin receptor antagonists Merck Sharp & Dohme Corp. 07/05/192D 3D TSV
US9745265 128 126 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 07/05/192D 3D TSV
US9745289 262 62 HGNC:2592 HGNC:2591 Aldosterone synthase inhibitors Boehringer Ingelheim International GmbH 07/05/192D 3D TSV
US9745304 64 32 Amidoimidazopyridazines as MKNK-1 kinase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 07/05/192D 3D TSV
US9744252 20 20 HGNC:6138 Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi PIRAMAL IMAGING SA 07/05/192D 3D TSV
US9745307 46 45 HGNC:6871 Compounds that are ERK inhibitors Merck Sharp & Dohme Corp. 07/05/192D 3D TSV
US9745328 898 885 HGNC:3650 Flap modulators Janssen Pharmaceutica NV 07/05/192D 3D TSV
US9745321 142 140 HGNC:8977 Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD 07/05/192D 3D TSV
US9745317 28 23 HGNC:3020 Heterocyclic compounds and their use as dopamine D1 ligands Pfizer Inc. 07/05/192D 3D TSV
US9745310 199 198 HGNC:4597 Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same SK BIOPHARMACEUTICALS CO., LTD. 07/05/192D 3D TSV
US9745324 83 44 HGNC:934 HGNC:933 Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 07/05/192D 3D TSV
US9745282 100 47 HGNC:2592 HGNC:2591 Indoline compounds as aldosterone synthase inhibitors Merck Sharp & Dohme Corp; ElexoPharm GmbH 07/05/192D 3D TSV
US9744148 96 90 HGNC:6368 Kallikrein 7 inhibitors SIXERA Pharma AB 07/05/192D 3D TSV
US9745291 277 274 HGNC:29652 PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof Epizyme, Inc. 07/05/192D 3D TSV
US9744172 287 286 HGNC:7027 Pyrazolopyrimidine compounds for the treatment of cancer The University of North Carolina at Chapel Hill 07/05/192D 3D TSV
US9745287 36 22 HGNC:10597 Pyrimidines and use thereof Purdue Pharma L.P. 07/05/192D 3D TSV
US9745311 266 89 HGNC:3690 HGNC:3689 HGNC:3688 Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors Incyte Corporation; Incyte Holdings Corporation 07/05/192D 3D TSV
US9745283 328 169 HGNC:7029 Uracil derivatives as AXL and c-MET kinase inhibitors IGNYTA, INC. 07/05/192D 3D TSV
US9738626 7 7 HGNC:9595 Antagonists of prostaglandin EP3 receptor Pfizer Inc. 07/01/192D 3D TSV
US9737516 44 18 Bicyclic heterocycles as bet protein inhibitors Incyte Corporation 07/01/192D 3D TSV
US9738641 20 10 HGNC:6371 HGNC:6357 Bicyclic inhibitors Kalvista Pharmaceuticals Limited 07/01/192D 3D TSV
US9737544 120 24 HGNC:6307 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Compounds ASTEX THERAPEUTICS LIMITED 07/01/192D 3D TSV
US9738658 36 36 HGNC:2843 Compounds as diacylglycerol acyltransferase inhibitors GlaxoSmithKline LLC 07/01/192D 3D TSV
US9738637 297 93 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors Celgene Quantical Research, Inc. 07/01/192D 3D TSV
US9738630 17 16 HGNC:3527 Inhibitors of lysine methyl transferase Bristol-Myers Squibb Company 07/01/192D 3D TSV
US9737522 17 17 NMDA receptor modulators and uses related thereto Emory University 07/01/192D 3D TSV
US9738632 20 18 HGNC:7978 Phenyl and benzodioxinyl substituted indazoles derivatives AstraZeneca AB; Bayer Pharma Aktiengesellschaft 07/01/192D 3D TSV
US9738668 30 9 Phosphonate derivatives and methods of use thereof in the treatment of Alzheimer's disease University of Kansas 07/01/192D 3D TSV
US9737542 111 111 HGNC:19679 Pyrrolotriazine kinase inhibitors Bristol-Myers Squibb Company 07/01/192D 3D TSV
US9738676 7 7 HGNC:8780 Selected macrolides with PDE4-inhibiting activity BASILEA PHARMACEUTICA AG 07/01/192D 3D TSV
US9737525 20 17 HGNC:10886 Small molecule activators of NRF2 pathway The General Hospital Corporation; The Regents of the University of California 07/01/192D 3D TSV
US9738628 36 21 Substituted 1H-indazol-1-OL analogs as inhibitors of beta catenin/Tcf protein-protein interactions University of Utah Research Foundation 07/01/192D 3D TSV
US9738640 16 8 HGNC:6833 HGNC:6834 Substituted benzamide derivatives as in vitro MAO-B inhibitors “NTZ LAB” LTD. 07/01/192D 3D TSV
US9738649 771 379 HGNC:12716 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. 07/01/192D 3D TSV
US9738655 635 318 HGNC:6371 HGNC:3529 Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors Bristol-Myers Squibb Company 07/01/192D 3D TSV
US9730929 33 33 HGNC:7110 Substituted aminoimidazopyridazines BAYER INTELLECTUAL PROPERTY GMBH 06/26/192D 3D TSV
US9732104 43 43 HGNC:2771 Ether compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 06/24/192D 3D TSV
US9732037 63 21 HGNC:7872 HGNC:7873 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors Northwestern University 06/23/192D 3D TSV
US9732060 560 555 HGNC:8534 Aminotriazine derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. 06/23/192D 3D TSV
US9732094 901 326 HGNC:6251 HGNC:9413 Arylquinazolines Merck Patent GmbH 06/23/192D 3D TSV
US9732075 1982 990 HGNC:4849 HGNC:4848 Benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD 06/23/192D 3D TSV
US9732088 116 39 HGNC:934 HGNC:2529 HGNC:933 C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 06/23/192D 3D TSV
US9732103 16 16 HGNC:2771 Carbamate, ester, and ketone compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 06/23/192D 3D TSV
US9732061 76 38 HGNC:2160 HGNC:2159 Cinnoline derivatives useful as CB-1 receptor inverse agonists Janssen Pharmaceutica NV 06/23/192D 3D TSV
US9732087 30 30 HGNC:17383 Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA N.V. 06/23/192D 3D TSV
US9732093 691 353 HGNC:3650 FLAP modulators JANSSEN PHARMACEUTICA NV 06/23/192D 3D TSV
US9732066 239 237 HGNC:9599 Heterocyclic derivative and pharmaceutical drug NIPPON SHINY AKU CO., LTD. 06/23/192D 3D TSV
US9730939 366 326 HGNC:8977 Heterocyclylamines as PI3K inhibitors Incyte Holdings Corporation; Incyte Corporation 06/23/192D 3D TSV
US9732063 194 72 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6874 Kinase inhibitors RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED 06/23/192D 3D TSV
US9732044 8 8 HGNC:644 N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use GALDERMA RESEARCH & DEVELOPMENT 06/23/192D 3D TSV
US9732072 30 29 HGNC:10894 PRMT5 inhibitors and uses thereof Epizyme, Inc. 06/23/192D 3D TSV
US9732097 26 26 HGNC:6190 Process for the synthesis of a phosphoinositide 3-kinase inhibitor Incyte Corporation 06/23/192D 3D TSV
US9730940 387 370 HGNC:8977 Purine inhibitors of human phosphatidylinositol 3-kinase delta Merck Sharp & Dohme 06/23/192D 3D TSV
US9732085 36 33 HGNC:3529 Pyridinone and pyrimidinone derivatives as factor Xia ONO PHARMACEUTICAL CO., LTD. 06/23/192D 3D TSV
US9730931 144 67 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Pyrimidine FGFR4 inhibitors EISAI R&D Management Co., Ltd. 06/23/192D 3D TSV
US9730934 33 11 HGNC:3432 HGNC:3430 HGNC:3236 Quinazoline derivatives substituted by aniline, preparation method and use thereof XUANZHU PHARMA CO., LTD. 06/23/192D 3D TSV
US9730937 1155 377 HGNC:9829 HGNC:1097 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION 06/23/192D 3D TSV
US9732092 23 23 HGNC:10966 Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections Gilead Sciences, Inc. 06/23/192D 3D TSV
US10196387 88 87 HGNC:13575 Carbazole compounds useful as bromodomain inhibitors Bristol-Myers Squibb Company 06/16/192D 3D TSV
US10196396 240 174 HGNC:268 HGNC:262 HGNC:263 Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof HANDOK INC. 06/16/192D 3D TSV
US10196436 116 57 HGNC:3691 HGNC:3688 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION 06/16/192D 3D TSV
US10196393 56 6 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 JAK inhibitors containing a 4-membered heterocyclic amide THERAVANCE BIOPHARMA R&D IP, LLC 06/16/192D 3D TSV
US10196404 3 1 HGNC:6943 MCL-1 inhibitors and methods of use thereof AstraZeneca AB 06/16/192D 3D TSV
US10196390 466 233 HGNC:6192 HGNC:12440 TYK2 inhibitors and uses thereof Nimbus Lakshmi, Inc. 06/16/192D 3D TSV
US10196391 120 119 Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection Hoffmann-La Roche Inc. 06/16/192D 3D TSV
US10196374 50 24 HGNC:7978 HGNC:11892 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as SGRM modulators AstraZeneca AB 06/14/192D 3D TSV
US10196354 127 127 HGNC:10260 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 06/14/192D 3D TSV
US10196381 41 41 HGNC:270 Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition containing the same, preparation method and use thereof SHANGHAI HUILUN LIFE SCIENCE &TECHNOLOGY CO., LTD 06/14/192D 3D TSV
US10196353 10 10 HGNC:8910 Chemical compounds GlaxoSmithKline Intellectual Property (No 2) Limited 06/14/192D 3D TSV
US10196378 44 9 HGNC:11283 HGNC:76 Inhibitors of BCR-ABL mutants and use thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN 06/14/192D 3D TSV
US10196365 22 11 HGNC:3430 HGNC:3236 Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof ARROMAX PHARMATECH CO., LTD. 06/14/192D 3D TSV
US10196369 103 102 HGNC:3128 Spirocyclic EBI2 modulators SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 06/14/192D 3D TSV
US10196373 93 86 HGNC:11364 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO; UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 06/14/192D 3D TSV
US10196383 8 4 HGNC:4849 HGNC:4848 Substituted quinazoline compounds and preparation and uses thereof SUNSHINE LAKE PHARMA CO., LTD. 06/14/192D 3D TSV
US10196385 3 3 HGNC:20088 Tetrahydropyranyl benzamide derivatives Eli Lilly and Company 06/14/192D 3D TSV
US10196382 6 6 bis-Pyridazine compounds and their use in treating cancer AstraZeneca AB; Cancer Research Technology Limited 06/14/192D 3D TSV
US9724347 120 32 HGNC:4840 HGNC:11491 HGNC:11283 HGNC:4617 HGNC:4616 HGNC:6874 HGNC:6876 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors Respivert, Ltd. 06/12/192D 3D TSV
US9725459 175 89 HGNC:2536 HGNC:2545 3-oxo-tetrahydro-furo[3,2-B]pyrrol-4(5H)-yl) derivatives I GRUNENTHAL GMBH 06/12/192D 3D TSV
US9725446 32 15 HGNC:8816 HGNC:11584 HGNC:14552 HGNC:11772 7-azaindole derivatives Merck Patent GmbH 06/12/192D 3D TSV
US9725465 406 201 HGNC:6342 HGNC:3765 Biaryl acetamide compounds and methods of use thereof Ambit Biosciences Corporation 06/12/192D 3D TSV
US10189849 50 45 HGNC:1771 HGNC:1773 CDK inhibitors G1 Therapeutics, Inc. 06/12/192D 3D TSV
US10195181 48 38 HGNC:16807 Carboxamide derivatives Novartis AG 06/12/192D 3D TSV
US9725433 164 146 HGNC:3763 HGNC:6307 Compounds as tyrosine kinase modulators ALLERGAN, INC. 06/12/192D 3D TSV
US10189853 42 15 HGNC:8803 HGNC:6307 HGNC:3236 Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents Duquesne University of the Holy Spirit 06/12/192D 3D TSV
US9725445 668 296 HGNC:6190 HGNC:6192 Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors Merck Sharp & Dohme Corp. 06/12/192D 3D TSV
US9725426 44 44 HGNC:2501 Cystathionine-γ-lyase (CSE) inhibitors SOVA PHARMACEUTICALS, INC. 06/12/192D 3D TSV
US9725436 51 17 Cytochrome P450 inhibitors and their method of use CORTENDO AB (PUBL) 06/12/192D 3D TSV
US10189859 236 91 HGNC:10597 Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine Nektar Therapeutics 06/12/192D 3D TSV
US10195178 99 98 HGNC:4498 GPR40 agonists in anti-diabetic drug combinations Janssen Pharmaceutica NV 06/12/192D 3D TSV
US10195201 75 32 HGNC:8777 Heteroaryl-pyrimidinone compounds as PDE2 inhibitors Merck Sharp & Dohme Corp. 06/12/192D 3D TSV
US9725442 422 338 HGNC:4502 Heterocyclic derivative having PGD2 receptor antagonist activity SHIONOGI & CO., LTD. 06/12/192D 3D TSV
US9724435 232 99 HGNC:3023 HGNC:11050 HGNC:8156 HGNC:11049 Highly selective sigma receptor ligands and radioligands as probes in nociceptive processing and the pathphysiological study of memory deficits and cognitive disorders THE UNIVERSITY OF MISSISSIPPI; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 06/12/192D 3D TSV
US9725441 199 93 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 06/12/192D 3D TSV
US9725434 62 31 HGNC:4849 HGNC:4848 Hydroxy-substituted orexin receptor antagonists MERCK SHARP & DOHME CORP. 06/12/192D 3D TSV
US10188639 3 3 HGNC:9236 Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone DeuteRx, LLC 06/12/192D 3D TSV
US10195186 101 49 HGNC:11186 N-substituted-5-substituted phthalamic acids as sortilin inhibitors H. Lundbeck A/S 06/12/192D 3D TSV
US10189791 5 5 HGNC:7873 Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole Trustees of Dartmouth College 06/12/192D 3D TSV
US9724352 7 7 HGNC:8979 Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Shanghai Haihe Pharmaceutical Co., Ltd. 06/12/192D 3D TSV
US9725439 29 20 HGNC:3236 Quinazoline derivative and preparation method therefor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.; CENTAURUS BIOPHARMA CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. 06/12/192D 3D TSV
US9725443 31 31 HGNC:10260 RORγ modulators Bristol-Myers Squibb Company 06/12/192D 3D TSV
US9725435 16 16 HGNC:3529 Substituted 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as factor XIa inhibitors Bristol-Myers Squibb Company 06/12/192D 3D TSV
US10196346 26 26 HGNC:4910 Substituted acethydrazide derivative, preparation method and use thereof Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China 06/12/192D 3D TSV
US10189854 347 343 HGNC:8781 Substituted pyrimidine compounds GRUENENTHAL GMBH 06/12/192D 3D TSV
US9725449 371 292 Tricyclic compounds as anticancer agents Bristol-Myers Squibb Company 06/12/192D 3D TSV
US9725430 18 12 HGNC:3521 HGNC:9642 Use of small molecule inhibitors targeting EYA tyrosine phosphatase CHILDREN HOSPITAL MEDICAL CENTER 06/12/192D 3D TSV
US10189796 9 9 HGNC:6018 [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof SANTEN PHARMACEUTICAL CO., LTD. 06/12/192D 3D TSV
US9663479 6 6 HGNC:1403 γ-aminobutyric acid (GABA) analogues for the treatment of pain and other disorders Novassay S.A. 06/04/192D 3D TSV
US9663475 31 28 HGNC:2529 2 amino-3,4-dihydrcquinazoline derivatives and the use thereof as cathepsin D inhibitors Merck Patent GmbH 06/04/192D 3D TSV
US9663502 580 573 HGNC:10260 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease Lycera Corporation; Merck Sharp & Dohme Corp. 06/04/192D 3D TSV
US9663522 43 40 HGNC:10260 3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 06/04/192D 3D TSV
US9663503 18 18 HGNC:1925 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof Cancer Research Technology Limited 06/04/192D 3D TSV
US9663530 136 67 5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives Hoffmann-La Roche Inc. 06/04/192D 3D TSV
US9663496 493 492 HGNC:9377 AMPK-activating heterocyclic compounds and methods for using the same Rigel Pharmaceuticals, Inc. 06/04/192D 3D TSV
US9663526 468 113 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Aminopyrimidinyl compounds Pfizer Inc. 06/04/192D 3D TSV
US9663498 53 53 HGNC:5301 Aromatic heterocyclic compounds and their application in pharmaceuticals SUNSHINE LAKE PHARMA CO., LTD. 06/04/192D 3D TSV
US9663470 177 176 HGNC:5208 Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline Vitae Pharmaceuticals, Inc.; Boehringer Ingelheim International Gmbh 06/04/192D 3D TSV
US9663523 56 56 HGNC:13575 BET protein-inhibiting 5-aryltriazoleazepines BAYER PHARMA AKTIENGESELLSCHAFT 06/04/192D 3D TSV
US9663508 431 308 HGNC:10593 HGNC:10597 Biaryl acyl-sulfonamide compounds as sodium channel inhibitors Amgen Inc. 06/04/192D 3D TSV
US9663519 33 33 HGNC:882 Compounds useful as inhibitors of ATR kinase Vertex Pharmaceuticals Incorporated 06/04/192D 3D TSV
US9663515 16 16 HGNC:10260 Dihydropyrrolopyridine inhibitors of ROR-gamma Vitae Pharmaceuticals, Inc. 06/04/192D 3D TSV
US9663527 4 4 HGNC:3529 Factor XIa inhibitors MERCK SHARP & DOHME CORP. 06/04/192D 3D TSV
US9663476 18 17 HGNC:11056 Glycine transporter-1 inhibitors AMGEN INC. 06/04/192D 3D TSV
US9663494 9 9 HGNC:1133 Inhibitors of bruton's tyrosine kinase Hoffmann-La Roche Inc. 06/04/192D 3D TSV
US9663543 33 33 HGNC:2771 Phosphonate compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 06/04/192D 3D TSV
US9663525 125 119 HGNC:12477 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme Millennium Pharmaceuticals, Inc. 06/04/192D 3D TSV
US9663513 257 224 HGNC:8772 Pyrimidine PDE10 inhibitors Merck Sharp & Dohme Corp. 06/04/192D 3D TSV
US9663506 315 292 HGNC:4594 Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use Merck Sharp & Dohme Corp. 06/04/192D 3D TSV
US9663511 44 21 HGNC:3169 HGNC:14299 Sphingosine 1-phosphate receptor antagonists Arroyo BioSciences, LLC 06/04/192D 3D TSV
US9663528 23 22 HGNC:10966 Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections Gilead Sciences, Inc. 06/04/192D 3D TSV
US9663510 28 28 HGNC:12401 Substituted triazolopyridines and their use as TTK inhibitors BAYER PHARMA AKTIENGESELLSCHAFT; BAYER INTELLECTUAL PROPERTY GMBH 06/04/192D 3D TSV
US9663529 96 96 HGNC:10252 Tricyclic pyrido-carboxamide derivatives as rock inhibitors Bristol-Myers Squibb Company 06/04/192D 3D TSV
US9663463 21 21 HGNC:8156 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose SANWA KAGAKU KENKYUSHO CO., LTD.; UBE INDUSTRIES, LTD. 06/03/192D 3D TSV
US9663465 50 26 HGNC:5299 HGNC:108 Acetylcholinesterase inhibitors and promnesiant serotonin 5-HT4 receptor agonists, their methods of preparation and the pharmaceutical compositions containing the same UNIVERSITE DE CAEN 06/03/192D 3D TSV
US9662330 243 240 HGNC:10436 Aminopyrimidine derivatives for use as modulators of kinase activity Merck Patent GmbH 06/03/192D 3D TSV
US9662339 296 295 HGNC:6710 Benzodioxane inhibitors of leukotriene production for combination therapy Boehringer Ingelheim International GmbH 06/03/192D 3D TSV
US9662310 68 66 HGNC:2300 Cyclopropanecarboxylic acid derivative DAIICHI SANKYO COMPANY, LIMITED 06/03/192D 3D TSV
US9662327 402 393 Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer AGIOS PHARMACEUTICALS, INC 06/03/192D 3D TSV
US9663469 319 307 RORγ modulators Bristol-Myers Squibb Company 06/03/192D 3D TSV
US9663460 209 209 HGNC:1603 Sulfur derivatives as chemokine receptor modulators ALLERGAN, INC. 06/03/192D 3D TSV
US10189845 867 207 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors Array BioPharma Inc. 05/29/192D 3D TSV
US9636336 248 55 HGNC:1952 Aminoester derivatives CHIESI FARMACEUTICI S.p.A. 05/29/192D 3D TSV
US9637499 10 10 HGNC:8780 Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors LEO PHARMA A/S 05/29/192D 3D TSV
US9637486 28 28 HGNC:1133 Btk inhibitors MERCK SHARP & DOHME CORP. 05/29/192D 3D TSV
US9637484 20 20 HGNC:17989 Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.; JIANGSU HENGRUI MEDICINE CO., LTD. 05/29/192D 3D TSV
US9636335 44 43 HGNC:5299 Heteroaryl compounds as 5-HT4 receptor ligands SUVEN LIFE SCIENCES LIMITED 05/29/192D 3D TSV
US9637488 37 33 HGNC:8978 Heterocyclic compounds as inhibitors of class I PI3KS TBA 05/29/192D 3D TSV
US9637455 21 21 Heterocyclic sulfone RORγ modulators Bristol-Myers Squibb Company 05/29/192D 3D TSV
US9636339 64 32 HGNC:2592 HGNC:2591 Phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors Hoffman-La Roche Inc. 05/29/192D 3D TSV
US9636338 48 23 HGNC:2592 HGNC:2591 Phenyl-dihydropyridine derivatives as inhibitors of aldosterone synthase Hoffmann-La Roche Inc. 05/29/192D 3D TSV
US9637487 34 34 HGNC:1133 Purinone compounds as kinase inhibitors PHARMACYCLICS LLC 05/29/192D 3D TSV
US10189841 544 538 HGNC:12607 Purinones as ubiquitin-specific protease 1 inhibitors FORMA Therapeutics, Inc. 05/29/192D 3D TSV
US9636337 315 292 HGNC:4594 Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use Merck Sharp & Dohme Corp. 05/29/192D 3D TSV
US9637472 391 389 HGNC:3527 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme, Inc. 05/29/192D 3D TSV
US9637496 1033 378 HGNC:4849 HGNC:4848 Substituted 7-azabicycles and their use as orexin receptor modulators Janssen Pharmaceutica NV 05/29/192D 3D TSV
US9637493 47 45 Substituted pyrrolopyrimidines as HDM2 inhibitors Merck Sharp & Dohme Corp. 05/29/192D 3D TSV
US10189840 40 40 HGNC:11892 Substituted tricyclic heterocyclic compounds Bristol-Myers Squibb Company 05/29/192D 3D TSV
US9636330 15 15 HGNC:3357 Tetrahydrocarboline derivative ONO PHARMACEUTICAL CO., LTD. 05/29/192D 3D TSV
US10189838 117 114 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection Hoffman-La Roche Inc. 05/26/192D 3D TSV
US10189835 22 21 Derivatives and methods of treating hepatitis B infections NOVIRA THERAPEUTICS, INC. 05/26/192D 3D TSV
US10189831 182 181 Non-nucleoside reverse transcriptase inhibitors Merck Sharp & Dohme Corp. 05/26/192D 3D TSV
US10189836 398 189 HGNC:6190 HGNC:6192 Therapeutic compounds, compositions and methods of use thereof Genentech, Inc. 05/26/192D 3D TSV
US10188615 195 171 HGNC:10294 HGNC:9864 HGNC:9866 HGNC:9865 HGNC:10477 Alkoxy compounds for disease treatment ACUCELA INC. 05/25/192D 3D TSV
US10188653 55 55 HGNC:16940 Diacylglycerol acyltransferase 2 inhibitors Pfizer Inc. 05/25/192D 3D TSV
US10189819 87 86 HGNC:3551 Factor IXa inhibitors Merck Sharp & Dohme, Corp.; Mochida Paraceuticals Co., Ltd. 05/25/192D 3D TSV
US10189794 194 192 HGNC:3691 Heteroaryl compounds and uses thereof Celgene CAR LLC; Sanofi 05/25/192D 3D TSV
US10188756 189 27 HGNC:4852 HGNC:14065 HGNC:14064 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 Imaging histone deacetylases with a radiotracer using positron emission tomography The General Hospital Corporation 05/25/192D 3D TSV
US10189829 145 139 HGNC:1133 Inhibiting agents for Bruton's tyrosine kinase BIOGEN MA INC. 05/25/192D 3D TSV
US10189805 8 8 HGNC:10943 Metabolism probes for therapy and diagnosis Vanderbilt University 05/25/192D 3D TSV
US10188758 8 5 HGNC:11050 HGNC:11048 Organic compounds INTRA-CELLULAR THERAPIES, INC. 05/25/192D 3D TSV
US10188627 67 32 HGNC:9235 PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof Mitobridge, Inc.; Salk Institute for Biological Studies 05/25/192D 3D TSV
US10188667 22 11 HGNC:4591 Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives ALLERGAN, INC. 05/25/192D 3D TSV
US10188642 104 103 HGNC:12401 Pharmacologically active compounds Cancer Research Technology Limited 05/25/192D 3D TSV
US10189809 198 191 HGNC:4685 SGC stimulators Ironwood Pharmaceuticals, Inc. 05/25/192D 3D TSV
US10189788 90 73 HGNC:9600 Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents BAYER PHARMA AKTIENGESELLSCHAFT 05/25/192D 3D TSV
US10189816 194 162 Substituted pyridines as inhibitors of human immunodeficiency virus replication ViiV HEALTHCARE UK (NO. 5) LIMITED 05/25/192D 3D TSV
US10189807 7 7 HGNC:23 Tetrahydrothiophene-based GABA aminotransferase inactivators Northwestern University 05/25/192D 3D TSV
US9630945 80 80 HGNC:10555 Autotaxin inhibitors Novartis AG 05/20/192D 3D TSV
US9630929 138 57 HGNC:10593 HGNC:10597 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 05/20/192D 3D TSV
US9629836 101 100 Compounds and compositions as inhibitors of MEK NOVARTIS AG 05/20/192D 3D TSV
US9630956 151 149 HGNC:882 Compounds useful as inhibitors of ATR kinase Vertex Pharmaceuticals Incorporated 05/20/192D 3D TSV
US9630965 73 63 HGNC:5253 HGNC:1735 Fused amino pyridine as HSP90 inhibitors Curis, Inc. 05/20/192D 3D TSV
US9630914 86 19 HGNC:3553 HGNC:9605 Multitarget FAAH and COX inhibitors and therapeutical uses thereof Fondazione Istituto Italiano Di Tecnologia; The Regents of the University of California; Alma Mater Studiorum—Universita' Di Bologna 05/20/192D 3D TSV
US9630949 143 77 HGNC:6932 HGNC:6929 Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT 05/20/192D 3D TSV
US9630931 29 29 HGNC:1925 Pharmaceutically active pyrazine derivatives SENTINEL ONCOLOGY LIMITED 05/20/192D 3D TSV
US10183937 838 407 HGNC:15459 HGNC:8534 1,3-thiazol-2-yl substituted benzamides Bayer Aktiengesellschaft 05/16/192D 3D TSV
US10179123 89 74 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 05/16/192D 3D TSV
US10174024 77 60 HGNC:13575 5H-pyrido[3,2-B]indole compounds as anticancer agents Bristol-Myers Squibb Company 05/16/192D 3D TSV
US10174035 234 135 HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors Daiichi Sankyo Company, Limited 05/16/192D 3D TSV
US10183940 124 78 HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists Boehringer Ingelheim International GmbH 05/16/192D 3D TSV
US10183025 206 200 HGNC:3357 Autotaxin inhibitors Novartis AG 05/16/192D 3D TSV
US10174049 36 36 HGNC:2843 Compounds as diacylglycerol acyltransferase inhibitors Glaxosmithkline LLC 05/16/192D 3D TSV
US10179761 52 28 HGNC:8157 Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases UNIVERSITE DE LILLE 2 DROIT ET SANTE; CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU) 05/16/192D 3D TSV
US10174030 116 116 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 05/16/192D 3D TSV
US10174037 579 205 HGNC:8777 Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors Merck Sharp & Dohme Corp. 05/16/192D 3D TSV
US10183939 56 21 Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers Redx Pharma PLC 05/16/192D 3D TSV
US10174044 63 62 HGNC:19679 Fused pyridines as kinase inhibitors Bristol-Myers Squibb Company 05/16/192D 3D TSV
US10183938 448 300 HGNC:5297 HGNC:1960 Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors Axovant Sciences GmbH 05/16/192D 3D TSV
US10174023 22 22 HGNC:270 Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD 05/16/192D 3D TSV
US10174026 297 93 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 05/16/192D 3D TSV
US10179769 211 103 HGNC:9886 HGNC:18039 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 05/16/192D 3D TSV
US10183928 8 4 HGNC:9967 Inhibitors of RET BLUEPRINT MEDICINES CORPORATION 05/16/192D 3D TSV
US10179773 10 10 HGNC:15513 Isoxazole carboxamides as irreversible SMYD inhibitors EPIZYME, INC. 05/16/192D 3D TSV
US10183942 112 16 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 JAK kinase inhibitor compounds for treatment of respiratory disease THERAVANCE BIOPHARMA R&D IP, LLC 05/16/192D 3D TSV
US10179804 132 132 HGNC:6932 Melanocortin receptor-specific peptides Palatin Technologies, Inc. 05/16/192D 3D TSV
US10183954 14 14 HGNC:15631 Oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection Hoffmann-La Roche Inc. 05/16/192D 3D TSV
US10183913 128 64 HGNC:11050 HGNC:5295 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. 05/16/192D 3D TSV
US10183947 51 49 HGNC:435 Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors ASTRAZENECA AB 05/16/192D 3D TSV
US10174020 10 10 HGNC:3529 Pyridone or pyrimidone derivative, preparation method therefor and application thereof SICHUAN HAISCO PHARMACEUTICAL CO., LTD. 05/16/192D 3D TSV
US10183944 614 335 HGNC:6192 HGNC:11491 Pyrimido-pyridazinone compounds and methods of use thereof Asana BioSciences, LLC 05/16/192D 3D TSV
US10174040 143 110 HGNC:1373 Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd. 05/16/192D 3D TSV
US10183931 91 36 HGNC:10251 HGNC:10252 Rho kinase inhibitors Kadmon Corporation, LLC 05/16/192D 3D TSV
US10179791 122 42 HGNC:3167 HGNC:3165 HGNC:14299 Spiro-cyclic amine derivatives as S1P modulators AbbVie B.V.; AbbVie, Inc. 05/16/192D 3D TSV
US10183953 990 258 HGNC:4849 HGNC:4848 Substituted 2-azabicycles and their use as orexin receptor modulators Janssen Pharmaceutica NV 05/16/192D 3D TSV
US10183932 357 143 HGNC:3529 Substituted oxopyridine derivatives and use thereof cardiovascular disorders Bayer Pharma Aktiengesellschaft 05/16/192D 3D TSV
US10174028 1162 716 HGNC:9967 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. 05/16/192D 3D TSV
US10174027 1162 716 HGNC:9967 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. 05/16/192D 3D TSV
US10183009 122 121 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 05/16/192D 3D TSV
US10183946 92 45 HGNC:2160 HGNC:2159 Triazolo[4,5-D]pyrimidines HOFFMANN-LA ROCHE INC. 05/16/192D 3D TSV
US10183917 18 17 HGNC:7967 Tricyclic compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. 05/16/192D 3D TSV
US10183021 388 384 HGNC:4685 sGC stimulators Ironwood Pharmaceuticals, Inc. 05/16/192D 3D TSV
US10174016 873 411 HGNC:2596 HGNC:2637 HGNC:15459 HGNC:2625 HGNC:8534 HGNC:2622 HGNC:2623 1,3-thiazol-2-yl substituted benzamides BEYER AKTIENGESELLSCHAFT 05/15/192D 3D TSV
US9624197 30 15 HGNC:4849 HGNC:4848 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists MERCK SHARP & DOHME CORP. 05/15/192D 3D TSV
US9624210 3 3 HGNC:11491 Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors MERCK SHARP & DOHME CORP. 05/15/192D 3D TSV
US10173985 34 18 HGNC:10593 HGNC:10597 Aminoindazole derivatives as sodium channel inhibitors Almirall, S.A. 05/15/192D 3D TSV
US9624159 8 8 HGNC:9596 Aniline derivatives, their preparation and their therapeutic application SANOFI 05/15/192D 3D TSV
US10174013 42 27 HGNC:6251 HGNC:3765 Benzimidazole derivatives as kinase inhibitors SELVITA S.A. 05/15/192D 3D TSV
US10174000 62 32 HGNC:17967 Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators Pfizer Inc. 05/15/192D 3D TSV
US9624235 20 15 HGNC:587 Compounds and methods for inhibition of AP endonuclease-1/redox factor-1 (HAPE1) activity University of Pittsburgh—Of the Commonwealth System of Higher Education 05/15/192D 3D TSV
US9624213 207 207 Compounds and methods for kinase modulation, and indications therefor Plexxikon Inc. 05/15/192D 3D TSV
US9624217 159 156 HGNC:10260 Dihydropyrrolopyridine inhibitors of ROR-gamma Vitae Pharmaceuticals, Inc. 05/15/192D 3D TSV
US9624175 82 61 Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. 05/15/192D 3D TSV
US9624194 25 22 HGNC:10597 Heteroaryl compounds as sodium channel blockers Purdue Pharma L.P. 05/15/192D 3D TSV
US9624234 25 24 HGNC:338 Heterocyclic compounds and methods for their use NOVARTIS AG 05/15/192D 3D TSV
US9624243 85 83 HGNC:338 Heterocyclic compounds and methods of their use NOVARTIS AG 05/15/192D 3D TSV
US10174011 307 98 HGNC:3023 HGNC:5286 HGNC:5293 Heterocyclic compounds, process for preparation of the same and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES; SUZHOU VIGONVITA LIFE SCIENCES CO., LTD.; TOPHARMAN SHANDONG CO., LTD. 05/15/192D 3D TSV
US10173996 511 154 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 05/15/192D 3D TSV
US10174003 329 106 HGNC:29012 HGNC:13606 HGNC:17071 HGNC:18039 HGNC:20672 HGNC:13610 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 05/15/192D 3D TSV
US9624188 12 12 HGNC:6059 IDO inhibitors Bristol-Myers Squibb Company 05/15/192D 3D TSV
US9624228 377 370 HGNC:6871 Inhibitors of ERK and methods of use Kura Oncology, Inc. 05/15/192D 3D TSV
US9624201 20 20 HGNC:1133 Inhibitors of bruton's tyrosine kinase HOFFMANN-LA ROCHE INC.; CHUGAI PHARMACEUTICAL CO. 05/15/192D 3D TSV
US9623028 67 28 HGNC:2068 HGNC:2069 HGNC:1470 HGNC:12401 Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof Signal Pharmaceuticals, LLC 05/15/192D 3D TSV
US10173988 15 5 HGNC:7889 HGNC:7891 HGNC:2578 N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine GLUCOX BIOTECH AB 05/15/192D 3D TSV
US9623021 24 12 HGNC:3467 HGNC:3468 Nuclear receptor binding agents GTX, Inc. 05/15/192D 3D TSV
US9624247 107 27 HGNC:13575 HGNC:1103 HGNC:2348 HGNC:1104 Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease NOVARTIS AG 05/15/192D 3D TSV
US9624246 30 15 HGNC:17967 Pyridazinone macrocycles as IRAK inhibitors and uses thereof Merck Patent GmbH 05/15/192D 3D TSV
US10173995 7 6 HGNC:8979 Pyridine compounds used as PI3 kinase inhibitors Teligene Ltd. 05/15/192D 3D TSV
US9624218 112 32 HGNC:270 HGNC:11941 HGNC:15677 Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors Eli Lilly and Company 05/15/192D 3D TSV
US10174007 40 18 HGNC:6315 Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors Pfizer Inc. 05/15/192D 3D TSV
US9624205 12 6 HGNC:3527 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme, Inc. 05/15/192D 3D TSV
US9624199 21 21 HGNC:277 Substituted bipiperidinyl derivatives Bayer Pharma Aktiengesellschaft 05/15/192D 3D TSV
US10174015 92 46 HGNC:3553 HGNC:736 Substituted heterocyclic derivative, preparation method and use thereof Xiamen University 05/15/192D 3D TSV
US9624198 15 14 HGNC:277 Substituted piperidinyltetrahydroquinolines Bayer Pharma Aktiengesellschaft 05/15/192D 3D TSV
US10172868 103 52 HGNC:6307 HGNC:1133 HGNC:6193 HGNC:3689 HGNC:3236 HGNC:3688 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. 05/15/192D 3D TSV
US10173991 590 589 HGNC:6623 Sulfone amide linked benzothiazole inhibitors of endothelial lipase Bristol-Myers Squibb Company 05/15/192D 3D TSV
US9624241 574 277 Tricyclic heterocycles as BET protein inhibitors Incyte Corporation; Incyte Holdings Corporation 05/15/192D 3D TSV
US10173990 17 17 HGNC:17989 URAT1 inhibitor Nippon Chemiphar Co., Ltd.; J-Pharma Co., Ltd.; DeThree Res. Lab. Inc. 05/15/192D 3D TSV
US9617246 74 36 HGNC:4849 HGNC:4848 Thioether-piperidinyl orexin receptor antagonists MERCK SHARP & DOHME CORP. 05/10/192D 3D TSV
US9617225 165 150 HGNC:1780 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity VIROSTATICS SRL 05/08/192D 3D TSV
US9617262 62 62 Antibacterial cyclopental[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones Janssen Sciences Ireland UC 05/08/192D 3D TSV
US9617267 761 86 HGNC:2596 HGNC:9829 HGNC:1097 HGNC:2637 HGNC:2625 HGNC:2623 HGNC:2621 Compounds and methods for kinase modulation, and indications therefor Plexxikon Inc. 05/08/192D 3D TSV
US9617226 45 44 HGNC:895 Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases AbbVie Deutschland GmbH & Co. KG 05/08/192D 3D TSV
US9617273 122 68 HGNC:270 HGNC:272 HGNC:15677 Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BeiGene, Ltd. 05/08/192D 3D TSV
US9617259 45 45 HGNC:14063 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI Foundation, Inc. 05/08/192D 3D TSV
US9617242 237 77 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 05/08/192D 3D TSV
US9617281 8 8 Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments LABORATORIES DEL DR. ESTEVE S.A. 05/08/192D 3D TSV
US9617260 34 34 HGNC:1133 Inhibitors of bruton's tyrosine kinase Hoffmann-La Roche Inc. 05/08/192D 3D TSV
US9617282 218 216 HGNC:17967 Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases BIOGEN MA INC. 05/08/192D 3D TSV
US9617269 97 96 HGNC:8795 N-substituted pyrazolo [3,4-D] pyrimidine ketone compound, and preparation process and use thereof Sun Yat-Sen University; University of North Carolina at Chapel Hill 05/08/192D 3D TSV
US9617239 89 88 HGNC:4696 Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase North Carolina Central University; The University of North Carolina at Chapel Hill 05/08/192D 3D TSV
US9617250 26 13 HGNC:3167 HGNC:3165 Pyridin-4-yl derivatives ACTELION PHARMACEUTICALS LTD. 05/08/192D 3D TSV
US9617258 611 315 HGNC:6193 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides Pfizer Inc. 05/08/192D 3D TSV
US9617261 11 11 HGNC:6840 Substituted pyridinone compounds as MEK inhibitors CMG PHARMACEUTICAL CO., LTD. 05/08/192D 3D TSV
US9617271 72 72 HGNC:8772 Triazolo compounds Hoffmann-La Roche Inc. 05/08/192D 3D TSV
US9617272 20 10 HGNC:11708 HGNC:6059 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization NewLink Genetics Corporation 05/08/192D 3D TSV
US9616063 30 15 HGNC:7218 HGNC:12015 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase AstraZeneca AB 05/07/192D 3D TSV
US9617222 48 48 HGNC:6307 Alkynyl indazole derivative and use thereof SENJU PHARMACEUTICAL CO., LTD. 05/07/192D 3D TSV
US9616064 137 77 HGNC:10251 HGNC:10252 Rho kinase inhibitors and methods of use H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 05/07/192D 3D TSV
US9616059 12 4 HGNC:5465 HGNC:11393 HGNC:427 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. 05/07/192D 3D TSV
US10172856 122 122 HGNC:17383 2,4-diaminopyrimidine derivatives as histamine H4 modulators Janssen Pharmaceutica NV 04/30/192D 3D TSV
US10172859 919 330 HGNC:6251 HGNC:9413 Arylquinazolines Merck Patent GmbH 04/30/192D 3D TSV
US9611269 84 42 HGNC:6190 HGNC:6192 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors Incyte Corporation; Incyte Holdings Corporation 04/30/192D 3D TSV
US10172858 368 95 HGNC:8979 HGNC:8978 HGNC:8980 HGNC:3942 HGNC:8977 Combination pharmaceutical compositions and uses thereof INTELLIKINE LLC 04/30/192D 3D TSV
US9611270 21 14 HGNC:2593 HGNC:2600 Inhibitors of CYP17A1 UNIVERSITY OF KANSAS 04/30/192D 3D TSV
US10172837 11 11 HGNC:1368 Insulin sensitisers and methods of treatment Naia Metabolic, Inc. 04/30/192D 3D TSV
US9611275 61 59 HGNC:7056 Permeable glycosidase inhibitors and uses thereof ALECTOS THERAPEUTICS, INC.; MERCK SHARP & DOHME CORP. 04/30/192D 3D TSV
US10172843 81 79 HGNC:2545 Piperidine derivatives Hoffmann-La Roche Inc. 04/30/192D 3D TSV
US9611277 990 259 HGNC:4849 HGNC:4848 Substituted 2-azabicycles and their use as orexin receptor modulators Janssen Pharmaceutica NV 04/30/192D 3D TSV
US10172845 2116 814 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. 04/30/192D 3D TSV
US10172851 1229 556 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. 04/30/192D 3D TSV
US10172814 213 157 HGNC:9605 Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof BAYER PHARMA AKTIENGESELLSCHAFT 04/30/192D 3D TSV
US10172864 1070 389 Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. 04/30/192D 3D TSV
US9611229 39 39 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders LABORATORIOS DEL DR. ESTEVE S.A. 04/29/192D 3D TSV
US9611249 35 34 HGNC:4617 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. 04/29/192D 3D TSV
US9611224 350 177 HGNC:590 HGNC:591 Antiproliferative benzo [B] azepin-2-ones HOFFMANN-LA ROCHE INC. 04/29/192D 3D TSV
US9610264 16 15 HGNC:6162 Compounds for the treatment and prevention of retroviral infections KFLP BIOTECH, LLC 04/29/192D 3D TSV
US9610299 42 12 HGNC:6833 HGNC:6834 HGNC:404 Compounds for the treatment of addiction Gilead Sciences, Inc. 04/29/192D 3D TSV
US9611221 199 93 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 04/29/192D 3D TSV
US9610322 10 10 HGNC:5381 Macrocyclic insulin-degrading enzyme (IDE) inhibitors and uses thereof President and Fellows of Harvard College 04/29/192D 3D TSV
US9611232 8 8 HGNC:6293 Oxazolidinone and imidazolidinone compounds Hoffmann-La Roche Inc. 04/29/192D 3D TSV
US9611261 846 397 HGNC:2529 HGNC:933 Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use Amgen Inc. 04/29/192D 3D TSV
US9611222 152 151 HGNC:10597 Pyridine compounds and the uses thereof Purdue Pharma L.P. 04/29/192D 3D TSV
US9611262 489 129 HGNC:4849 HGNC:4848 Substituted 2-azabicycles and their use as orexin receptor modulators Janssen Pharmaceutica NV 04/29/192D 3D TSV
US9611251 546 192 HGNC:4849 HGNC:4848 Substituted piperidine compounds and their use as orexin receptor modulators Janssen Pharmaceutica NV 04/29/192D 3D TSV
US9611259 3 3 HGNC:2433 Substituted pyridine derivatives useful as C-FMS kinase inhibitors Janssen Pharmaceutica NV 04/29/192D 3D TSV
US9611267 699 232 HGNC:3690 HGNC:3689 HGNC:3688 Substituted tricyclic compounds as FGFR inhibitors Incyte Holdings Corporation; Incyte Corporation 04/29/192D 3D TSV
US9611252 146 145 HGNC:6371 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. 04/29/192D 3D TSV
US9611265 241 79 HGNC:8031 HGNC:8032 HGNC:8033 HGNC:2433 Tropomyosin-related kinase (TRK) inhibitors GENZYME CORPORATION 04/29/192D 3D TSV
US10167299 125 111 HGNC:1606 HGNC:6251 1-(3-aminopropyl) substituted cyclic amine compounds, preparation method therefor, and pharmaceutical compositions and uses thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 04/24/192D 3D TSV
US10167282 14 5 HGNC:6251 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer CANCER RESEARCH TECHNOLOGY LIMITED; INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) 04/24/192D 3D TSV
US9605007 135 118 HGNC:6251 HGNC:933 HGNC:2625 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides Pfizer Inc. 04/24/192D 3D TSV
US10167261 20 9 2-oxo-3,4-dihydroquinolin-6-yl sulphonamide CPDS and their use as plant growth regulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; SYNGENTA PARTICIPATIONS AG 04/24/192D 3D TSV
US9605006 15 15 HGNC:933 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines Hoffmann-La Roche Inc. 04/24/192D 3D TSV
US9605005 199 198 HGNC:5960 Alkynyl alcohols and methods of use Genentech, Inc. 04/24/192D 3D TSV
US10167292 172 37 Benzodiazepines as bromodomain inhibitors Catalyst Therapeutics Pty Ltd. 04/24/192D 3D TSV
US9605008 21 21 HGNC:8784 Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof BAYER PHARMA AKTIENGESELLSCHAFT 04/24/192D 3D TSV
US10167279 409 305 HGNC:9829 Compounds and compositions as RAF kinase inhibitors Novartis AG 04/24/192D 3D TSV
US10167276 207 69 Compounds and methods for inhibiting JAK Dizal (Jiangsu) Pharmaceutical Co., Ltd. 04/24/192D 3D TSV
US9604998 109 95 HGNC:6255 Inhibitors of the renal outer medullary potassium channel Merck Sharp & Dohme Corp. 04/24/192D 3D TSV
US9605022 39 20 HGNC:592 Macrocyclic compounds for inhibition of inhibitors of apoptosis Ensemble Therapeutics Corporation 04/24/192D 3D TSV
US9605024 9 9 HGNC:3540 PAR4 agonist peptides Bristol-Myers Squibb Company 04/24/192D 3D TSV
US10167256 8 4 HGNC:3023 Psychotrophic agents and uses thereof LB PHARMACEUTICALS INC. 04/24/192D 3D TSV
US10167313 102 25 HGNC:1506 HGNC:1508 HGNC:1504 HGNC:1499 HGNC:1511 Selective caspase inhibitors and uses thereof Genesis Technologies Limited 04/24/192D 3D TSV
US10167285 48 16 HGNC:3430 HGNC:5253 Small-molecule HSP90 inhibitors Memorial Sloan Kettering Cancer Center 04/24/192D 3D TSV
US10166249 952 228 HGNC:3167 HGNC:10817 Substituted bicyclic compounds Bristol-Myers Squibb Company 04/24/192D 3D TSV
US10167280 108 47 HGNC:3529 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT 04/24/192D 3D TSV
US10167264 10 5 HGNC:3236 Substituted pyrimidines useful as EGFR-T790M kinase inhibitors Jiangsu Medolution Ltd 04/24/192D 3D TSV
US10167270 175 127 HGNC:4177 Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity Northwestern University 04/24/192D 3D TSV
US10167281 213 119 HGNC:8537 Substituted thiazole or oxazole P2X7 receptor antagonists Axxam S.P.A. 04/24/192D 3D TSV
US10166216 151 151 Substituted triazoles useful as Axl inhibitors Rigel Pharmaceuticals, Inc. 04/24/192D 3D TSV
US10167273 111 107 HGNC:4524 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases Takeda Pharmaceutical Company Limited 04/24/192D 3D TSV
US10167296 99 67 HGNC:7110 HGNC:7111 Sulfoximine substituted quinazolines for pharmaceutical compositions EVOTEC INTERNATIONAL GMBH 04/24/192D 3D TSV
US10166239 241 78 HGNC:8031 HGNC:8032 HGNC:8033 HGNC:2433 Tropomyosin-related kinase (Trk) inhibitors Genzyme Corporation 04/24/192D 3D TSV
US10167293 76 76 HGNC:386 [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones BAYER PHARMA AKTIENGESELLSCHAFT 04/24/192D 3D TSV
US9603834 27 26 HGNC:1603 1,2- bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN, INC. 04/23/192D 3D TSV
US9604984 934 465 HGNC:6190 HGNC:6192 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof Genentech, Inc. 04/23/192D 3D TSV
US9604960 81 27 HGNC:11050 HGNC:11048 HGNC:11049 Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof Albany Molecular Research, Inc. 04/23/192D 3D TSV
US9604944 6 2 HGNC:5286 HGNC:5293 Arylpiperazine derivatives and methods of utilizing same REVIVA PHARMACEUTICALS, INC. 04/23/192D 3D TSV
US9603833 88 42 HGNC:6833 HGNC:6834 HGNC:550 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-Tech Ueno, Ltd. 04/23/192D 3D TSV
US9604977 516 251 HGNC:3560 HGNC:3559 Bicyclic thiophenylamide compounds Hoffman-La Roche Inc. 04/23/192D 3D TSV
US9604926 226 99 HGNC:3023 HGNC:4584 HGNC:11050 HGNC:8156 HGNC:5293 HGNC:11048 HGNC:11049 Highly selective sigma receptor radioligands THE UNIVERSITY OF MISSISSIPPI 04/23/192D 3D TSV
US9604961 509 153 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 04/23/192D 3D TSV
US9603889 86 43 HGNC:592 IAP antagonists Bristol-Myers Squibb Company 04/23/192D 3D TSV
US9604989 159 80 HGNC:391 HGNC:392 Imidazopyridazines as Akt kinase inhibitors BAYER INTELLECTUAL PROPERTY GMBH; BAYER PHARMA AKTIENGESELLSCHAFT 04/23/192D 3D TSV
US9603854 119 113 HGNC:990 Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER; VERNALIS (R&D) LTD 04/23/192D 3D TSV
US9604931 24 12 HGNC:3473 HGNC:3471 Nuclear receptor binding agents GTx, Inc.; THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 04/23/192D 3D TSV
US9604982 678 116 HGNC:8537 P2X7 modulators Janssen Pharmaceutica NV 04/23/192D 3D TSV
US9603836 28 27 HGNC:6059 Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors ITEOS THERAPEUTICS 04/23/192D 3D TSV
US9603819 13 13 HGNC:7154 Substituted aminobutyric derivatives as neprilysin inhibitors NOVARTIS AG 04/23/192D 3D TSV
US9604945 7 7 HGNC:11049 Sydnonimines-specific dopamine reuptake inhibitors and their use in treating dopamine related disorders Caliper Life Sciences, Inc. 04/23/192D 3D TSV
US10166226 9 9 CGRP receptor antagonists Heptares Therapeutics Limited 04/11/192D 3D TSV
US10166229 10 10 HGNC:1504 Compounds and methods for the treatment of cancer The Board of Trustees of the University of Illinois 04/11/192D 3D TSV
US10155763 7 7 HGNC:11772 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors TIUMBIO CO., LTD. 04/10/192D 3D TSV
US10155750 76 38 HGNC:4849 HGNC:4848 Amidoethyl azole orexin receptor antagonists Merck Sharp & Dohme Corp. 04/10/192D 3D TSV
US10155760 237 234 HGNC:19679 Biaryl kinase inhibitors Bristol-Myers Squibb Company 04/10/192D 3D TSV
US10155765 66 66 HGNC:17967 Carboxamide inhibitors of IRAK4 activity Merck Sharp & Dohme Corp. 04/10/192D 3D TSV
US10155769 91 91 HGNC:1406 Fused azaheterocyclic compounds and their use as AMPA receptor modulators Janssen Pharmaceutica NV 04/10/192D 3D TSV
US10155768 520 197 HGNC:9967 Fused pyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd. 04/10/192D 3D TSV
US10155752 16 12 HGNC:10597 Indazoles and use thereof Purdue Pharma L.P. 04/10/192D 3D TSV
US10155733 27 27 HGNC:1952 N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same Conopco, Inc. 04/10/192D 3D TSV
US10155731 131 127 HGNC:9958 Nitrogen-containing saturated heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION; SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. 04/10/192D 3D TSV
US10155751 81 27 Pyrazolyl-substituted heteroaryls and their use as medicaments Boehringer Ingelheim International GmbH 04/10/192D 3D TSV
US10155732 5 5 HGNC:10452 Ribonucleotide reductase inhibitors and methods of use City of Hope 04/10/192D 3D TSV
US10155972 10 6 HGNC:11708 Screening method Iomet Pharma Ltd. 04/10/192D 3D TSV
US10166214 284 169 HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 Somatostatin receptor subtype 4 (SSTR4) agonists Centrexion Therapeutics Corporation 04/10/192D 3D TSV
US10155775 8 8 HGNC:3009 Substituted amino six-membered saturated heteroalicycles as long-acting DPP-IV inhibitors Centaurus Biopharma Co., Ltd.; Chia Tai Tianqing Pharmaceutical Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd. 04/10/192D 3D TSV
US10155764 114 111 Therapeutic compounds and uses thereof GENENTECH, INC; CONSTELLATION PHARMACEUTICALS, INC. 04/10/192D 3D TSV
US10150759 3 3 HGNC:3527 1,4-pyridone bicycic heteroaryl compounds Epizyme, Inc. 04/09/192D 3D TSV
US10150755 127 89 HGNC:6857 HGNC:7590 HGNC:11892 ASK1 inhibitor compounds and uses thereof SEAL ROCK THERAPEUTICS, INC. 04/09/192D 3D TSV
US9657003 40 20 Androgen receptor modulating compounds ORION CORPORATION 04/09/192D 3D TSV
US10155722 20 20 HGNC:5383 Antitumor compound targeting IDH2 mutation and method of use thereof Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd.; Centaurus Biopharma Co., Ltd. 04/09/192D 3D TSV
US10155002 334 185 HGNC:3527 Aryl- or heteroaryl-substituted benzene compounds Epizyme, Inc. 04/09/192D 3D TSV
US9657001 65 65 HGNC:6719 Compounds and uses ASTRAZENECA AB 04/09/192D 3D TSV
US10150760 390 224 HGNC:339 Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor AMGEN INC. 04/09/192D 3D TSV
US9656996 17 17 HGNC:11892 Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. 04/09/192D 3D TSV
US9657009 168 150 HGNC:17967 Heteroaryl substituted pyridyl compounds useful as kinase modulators Bristol-Myers Squibb Company 04/09/192D 3D TSV
US10150763 76 38 HGNC:4852 HGNC:14064 Histone deacetylase inhibitors and their use in therapy Karus Therapeutics Limited 04/09/192D 3D TSV
US9656988 1351 352 HGNC:1133 HGNC:6193 HGNC:3236 HGNC:6524 Inhibitors of Bruton's tyrosine kinase PHARMACYCLICS LLC 04/09/192D 3D TSV
US9656991 121 70 HGNC:9753 Inhibitors of glutaminyl cyclase PROBIODRUG AG 04/09/192D 3D TSV
US10150765 843 286 HGNC:8537 P2X7 modulators Janssen Pharmaceutica NV 04/09/192D 3D TSV
US10150766 102 62 HGNC:8537 P2X7 modulators Janssen Pharmaceutica NV 04/09/192D 3D TSV
US10150758 30 29 HGNC:10894 PRMT5 inhibitors and uses thereof Epizyme, Inc. 04/09/192D 3D TSV
US10155727 217 103 HGNC:4586 HGNC:6251 Pyrazoles JANSSEN PHARMACEUTICALS, INC. 04/09/192D 3D TSV
US9657007 36 18 HGNC:8979 HGNC:8978 HGNC:8977 HGNC:8976 Substituted aminopyrimidine compounds and methods of use CALITOR SCIENCES, LLC; SUNSHINE LAKE PHARMA CO., LTD. 04/09/192D 3D TSV
US10150764 139 70 HGNC:3527 Substituted benzene compounds Epizyme, Inc. 04/09/192D 3D TSV
US9657015 73 49 HGNC:3309 Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 04/09/192D 3D TSV
US10150787 10 10 HGNC:9650 TC-PTP inhibitors as APC activators for immunotherapy TBA 04/09/192D 3D TSV
US9657033 112 92 HGNC:10260 Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease Lycera Corporation; Merck Sharp & Dohme Corp. 04/09/192D 3D TSV
US10150767 46 45 Therapeutic compounds and uses thereof Genentech, Inc.; Constellation Pharmaceuticals Inc. 04/09/192D 3D TSV
US10150762 178 86 HGNC:10260 Trifluoromethyl alcohols as modulators of RORγt Janssen Pharmaceutica, NV 04/09/192D 3D TSV
US9656975 20 10 HGNC:4579 Bicyclo[3.2.1]octyl amide derivatives and uses of same H. Lundbeck A/S 04/08/192D 3D TSV
US9655879 188 94 HGNC:9490 HGNC:9475 Heteroarylcarboxylic acid ester derivative EA Pharma Co., Ltd. 04/08/192D 3D TSV
US9656961 158 54 HGNC:8156 Methods for treating depressive symptoms ALKERMES PHARMA IRELAND LIMITED 04/08/192D 3D TSV
US9656968 122 102 HGNC:10597 Pyrimidines as sodium channel blockers TBA 04/08/192D 3D TSV
US9656955 808 790 HGNC:7044 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy AbbVie Inc.; AbbVie Deutschland GmbH & Co. KG 04/08/192D 3D TSV
US9656962 87 47 HGNC:8153 HGNC:8154 HGNC:8155 HGNC:8156 Ring-contracted morphinans and the use thereof Purdue Pharma L.P. 04/08/192D 3D TSV
US9656959 90 77 HGNC:10597 Substituted pyridines as sodium channel blockers Purdue Pharma L.P. 04/08/192D 3D TSV
US9649308 246 175 HGNC:8537 Benzamide-containing compounds and their use in the treatment of pain H. Lundbeck A/S 04/03/192D 3D TSV
US9650377 368 161 HGNC:4597 HGNC:4593 Diazepinone derivatives Novartis AG 04/03/192D 3D TSV
US9650366 16 13 HGNC:6307 HGNC:8804 HGNC:9437 Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors ALLERGAN, INC. 04/03/192D 3D TSV
US9650362 20 10 HGNC:9753 Inhibitors PROBIODRUG AG 04/03/192D 3D TSV
US9650336 11 11 Mono-fluoro beta-secretase inhibitors ASTRAZENECA AB 04/03/192D 3D TSV
US9650358 339 335 HGNC:1780 Pyridine CDK9 kinase inhibitors AbbVie Inc. 04/03/192D 3D TSV
US9650371 37 37 HGNC:933 Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity Shionogi & Co., Ltd. 04/03/192D 3D TSV
US9649309 1394 400 HGNC:7027 HGNC:12446 HGNC:3765 Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity The University of North Carolina at Chapel Hill 04/03/192D 3D TSV
US10150740 15 15 6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection Hoffmann-La Roche Inc. 03/31/192D 3D TSV
US10150728 704 701 HGNC:85 Alkylene derivatives SHIONOGI & CO., LTD. 03/31/192D 3D TSV
US10144746 350 344 HGNC:6371 Bridged bicyclic kallikrein inhibitors Global Blood Therapeutics, Inc. 03/31/192D 3D TSV
US10150743 28 13 HGNC:15631 HGNC:15632 Carboxylic acid compounds Sumitomo Dainippon Pharma Co., Ltd. 03/31/192D 3D TSV
US10149839 156 72 HGNC:3467 Chemical compounds AstraZeneca AB 03/31/192D 3D TSV
US10149841 6 6 HGNC:1232 Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. 03/31/192D 3D TSV
US10150747 65 31 Compounds for the treatment of hepatitis C Bristol-Myers Squibb Company 03/31/192D 3D TSV
US10149835 7 7 HGNC:7967 Isoxazole derivatives as FXR agonists and methods of use thereof Elmore Patent Law Group, P.C. 03/31/192D 3D TSV
US10149840 3 3 HGNC:9221 OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 03/31/192D 3D TSV
US10150751 82 41 HGNC:4849 HGNC:4848 Pyrrolidine orexin receptor antagonists Merck Sharp & Dohme Corp. 03/31/192D 3D TSV
US10143681 183 71 HGNC:6371 HGNC:3529 Factor XIa inhibitors Merck Sharp & Dohme Corp. 03/30/192D 3D TSV
US10138245 14 14 HGNC:8772 Fused triazole derivatives as phosphodiesterase 10A inhibitors CELON PHARMA S.A. 03/30/192D 3D TSV
US10143668 5 5 HGNC:4879 Hydroxy-substituted amino and ammonium derivatives and their medical use GRI BIO, INC. 03/30/192D 3D TSV
US10138253 38 28 Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication ViiV HEALTHCARE UK (NO.5) LIMITED 03/30/192D 3D TSV
US10143746 28 28 Immunomodulators Bristol-Myers Squibb Company 03/30/192D 3D TSV
US10144729 8 8 HGNC:7967 Isoxazole analogs as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. 03/30/192D 3D TSV
US10143704 1 1 Methods for treating cancer Epizyme, Inc. 03/30/192D 3D TSV
USRE47141 78 78 HGNC:11772 Methods of treating fibrosis, cancer and vascular injuries EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION 03/30/192D 3D TSV
US10144731 519 257 HGNC:7782 Nrf2 regulators GlaxoSmithKline Intellectual Property Development Limited; Astex Therapeutics, Ltd 03/30/192D 3D TSV
US10144715 925 407 HGNC:7966 HGNC:7965 Piperazine derivatives as liver X receptor modulators Vitae Pharmaceuticals, Inc. 03/30/192D 3D TSV
US10144738 148 35 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives Pfizer Inc. 03/30/192D 3D TSV
US10138242 229 112 HGNC:8856 Pyrazolopyridine derivatives and their use in therapy TBA 03/30/192D 3D TSV
US10143695 130 26 HGNC:3430 Pyrrolobenzodiazepines and conjugates thereof Mersana Therapeutics, Inc. 03/30/192D 3D TSV
US10144742 520 520 HGNC:30092 Quinoxaline compounds and uses thereof Millennium Pharmaceuticals, Inc. 03/30/192D 3D TSV
US10144734 2116 812 HGNC:9967 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. 03/30/192D 3D TSV
US10138249 20 20 HGNC:29079 Triazolopyridines and triazolopyrazines as LSD1 inhibitors Incyte Corporation 03/30/192D 3D TSV
US10137110 81 46 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors Bayer Pharma Aktiengesellschaft 03/29/192D 3D TSV
US9597318 7 7 HGNC:9035 2-oxothiazole compounds and method of using same for chronic inflammatory disorders Avexxin AS 03/29/192D 3D TSV
US9598446 65 65 HGNC:2771 Amino compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. 03/29/192D 3D TSV
US10138212 111 111 HGNC:263 Aminoquinazoline compounds as A2A antagonist Merck Sharp & Dohme Corp. 03/29/192D 3D TSV
US9598407 41 41 Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones Janssen Sciences Ireland UC 03/29/192D 3D TSV
US10137202 11 6 HGNC:3590 Antibody-drug conjugates and immunotoxins Oncomatryx Biopharma, S.L. 03/29/192D 3D TSV
US10138230 125 123 HGNC:3357 Autotaxin inhibitors Cancer Research Technology Limited 03/29/192D 3D TSV
US9597333 160 79 HGNC:15631 HGNC:15632 Benzazepine dicarboxamide compounds Hoffmann-La Roche Inc. 03/29/192D 3D TSV
US10138226 44 35 Benzimidazol-2-amines as MIDH1 inhibitors Bayer Pharma Aktiengesellschaft 03/29/192D 3D TSV
US9597326 26 26 HGNC:15631 Benzonapthyridine compositions and uses thereof GlaxoSmithKline Biologicals SA; U.S. Army Medical Research and Materiel Command 03/29/192D 3D TSV
US10131670 108 36 HGNC:1884 Bicyclic heteroaryl derivatives as CFTR potentiators CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. 03/29/192D 3D TSV
US10131663 194 70 HGNC:6251 HGNC:3467 Chemical compounds AstraZeneca AB 03/29/192D 3D TSV
US9598415 265 261 HGNC:10260 Compounds as modulators of RORγ Boehringer Ingelheim International GmbH 03/29/192D 3D TSV
US9598431 15 4 HGNC:10259 HGNC:10258 HGNC:10260 Compounds useful for inhibiting ROR-gamma-t Eli Lilly and Company 03/29/192D 3D TSV
US10138240 2 2 Crystal of 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative Daiichi Sankyo Company, Limited 03/29/192D 3D TSV
US9597330 60 48 HGNC:10597 Drugs for treating respiratory diseases Daiichi Sankyo Company, Limited 03/29/192D 3D TSV
US10138236 66 33 HGNC:6371 HGNC:3529 Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives BAYER PHARMA AKTIENGESELLSCHAFT 03/29/192D 3D TSV
US10138229 156 149 HGNC:1133 Heteroaromatic compounds as BTK inhibitors Boehringer Ingelheim International GmbH 03/29/192D 3D TSV
US9598421 372 103 HGNC:8780 HGNC:8782 HGNC:8781 HGNC:8783 Imidazopyridazine compounds Pfizer Inc. 03/29/192D 3D TSV
US9597310 65 65 HGNC:4498 Indanyloxydihydrobenzofuranylacetic acids Boehringer Ingelheim International GmbH 03/29/192D 3D TSV
US9598440 159 158 HGNC:17967 Inhibitors of IRAK4 activity MERCK SHARP & DOHME CORP. 03/29/192D 3D TSV
US10131664 178 174 HGNC:29079 Inhibitors of lysine specific demethylase-1 Celgene Quanticel Research, Inc. 03/29/192D 3D TSV
US10138228 4 4 HGNC:7967 Isoxazole derivatives as FXR agonists and methods of use therof ENANTA PHARMACEUTICALS, INC. 03/29/192D 3D TSV
US10137122 244 116 HGNC:2452 HGNC:4617 HGNC:4616 Kinase inhibitors and methods of use thereof The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.; The General Hospital Corporation 03/29/192D 3D TSV
US9598426 8 4 HGNC:8775 HGNC:8774 Organic compounds INTRA-CELLULAR THERAPIES, INC. 03/29/192D 3D TSV
US9598447 72 14 HGNC:8153 HGNC:8154 HGNC:8155 HGNC:8156 Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof Purdue Pharma L.P. 03/29/192D 3D TSV
US10131673 42 41 Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) Janssen Sciences Ireland UC 03/29/192D 3D TSV
US9598370 55 24 HGNC:1232 HGNC:12680 HGNC:14661 Prolyl hydroxylase inhibitors and methods of use Akebia Therapeutics, Inc. 03/29/192D 3D TSV
US9598381 18 17 HGNC:20982 SMYD2 inhibitors AbbVie Inc. 03/29/192D 3D TSV
US9598410 68 64 HGNC:6278 Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them SANOFI 03/29/192D 3D TSV
US9598423 827 421 HGNC:2453 HGNC:2452 Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors Bristol-Myers Squibb Company 03/29/192D 3D TSV
US10138222 122 120 HGNC:10020 Substituted benzamides as RIPK2 inhibitors Boehringer Ingelheim International GmbH 03/29/192D 3D TSV
US10138241 97 97 HGNC:10020 Substituted benzamides as RIPK2 inhibitors Boehringer Ingelheim International GmbH 03/29/192D 3D TSV
US9598411 172 73 HGNC:8153 HGNC:8154 HGNC:8155 HGNC:8156 Substituted benzimidazole-type piperidine compounds and uses thereof Purdue Pharma L.P. 03/29/192D 3D TSV
US9598416 159 83 HGNC:3690 HGNC:3688 Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer BAYER INTELLECTUAL PROPERTY GMBH 03/29/192D 3D TSV
US9598436 18 18 HGNC:2593 Substituted bicyclic heteroaryl compounds Bristol-Myers Squibb Company 03/29/192D 3D TSV
US9598401 63 46 HGNC:5286 Substituted heteroaryl compounds and methods of use thereof SUNSHINE LAKE PHARMA CO., LTD. 03/29/192D 3D TSV
US9597317 74 37 HGNC:6342 HGNC:3765 Substituted indazole derivatives active as kinase inhibitiors NERVIANO MEDICAL SCIENCES S.R.L. 03/29/192D 3D TSV
US10137124 1229 557 HGNC:9967 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. 03/29/192D 3D TSV
US10131667 699 231 HGNC:3690 HGNC:3689 HGNC:3688 Substituted tricyclic compounds as FGFR inhibitors Incyte Corporation 03/29/192D 3D TSV
US9598396 39 19 HGNC:270 HGNC:15677 Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors Janssen Pharmaceutica NV 03/29/192D 3D TSV
US9598405 52 44 HGNC:11491 Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors Merck Sharp & Dohme Corp. 03/29/192D 3D TSV
US10137210 9 9 HGNC:620 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition The University of Pittsburgh—Of the Commonwealth System of Higher Education 03/29/192D 3D TSV
US10131675 153 152 HGNC:6851 Tricyclic DLK inhibitors and uses thereof Genentech, Inc. 03/29/192D 3D TSV
US9598387 260 129 HGNC:3023 HGNC:3024 Urea and amide derivatives of aminoalkylpiperazines and use thereof Southern Research Institute 03/29/192D 3D TSV
US10131692 88 43 HGNC:897 HGNC:896 Vasopressin-2 receptor agonists Ferring B.V. 03/29/192D 3D TSV
US10130619 70 70 HGNC:7889 Amido thiadiazole derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA 03/28/192D 3D TSV
US10131658 37 34 HGNC:6141 Anti-alphavbeta1 integrin compounds and methods The Regents of the University of California 03/28/192D 3D TSV
US10131645 33 33 Benzofurans substituted with primary benzamide as HCV inhibitors Bristol-Myers Squibb Company 03/28/192D 3D TSV
US10130617 18 9 HGNC:3467 Chemical compounds AstraZeneca AB 03/28/192D 3D TSV
US10130633 700 254 HGNC:15983 Compounds BAYER PHARMA AKTIENGESELLSCHAFT 03/28/192D 3D TSV
US10130622 11 4 HGNC:1884 Compounds for treatment of cystic fibrosis AbbVie S.á.r.l.; Galapagos NV 03/28/192D 3D TSV
US10130642 65 64 HGNC:7154 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC 03/28/192D 3D TSV
US10131648 98 97 HGNC:4498 Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes Janssen Pharmaceutica NV 03/28/192D 3D TSV
US10131651 13 9 HGNC:4498 [7,6]-fused bicyclic antidiabetic compounds Merck Sharp & Dohme Corp. 03/28/192D 3D TSV
US9593097 435 405 Axl inhibitors Pfizer Inc. 03/15/192D 3D TSV
US9593099 22 22 HGNC:1097 Compounds and compositions as protein kinase inhibitors Array BioPharma, Inc. 03/15/192D 3D TSV
US9593100 23 23 HGNC:1097 Compounds and compositions as protein kinase inhibitors Array BioPharma, Inc. 03/15/192D 3D TSV
US9593127 20 20 HGNC:4597 Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors RECORDATI IRELAND LTD. 03/15/192D 3D TSV
US9593123 194 97 HGNC:2160 HGNC:2159 Triazolo[4,5-D]pyrimidine derivatives Hoffmann-La Roche Inc. 03/15/192D 3D TSV
US9592235 219 214 HGNC:6866 Aminoquinazoline and pyridopyrimidine derivatives Genentech, Inc. 03/14/192D 3D TSV
US9593105 223 144 HGNC:8537 Cyclic amines H. Lundbeck A/S 03/14/192D 3D TSV
US9593110 201 168 HGNC:7154 Neprilysin inhibitors Theravence Biopharma R&D IP, LLC 03/14/192D 3D TSV
US9592230 125 125 HGNC:8772 Substituted imidazoles as PDE10A inhibitors H. Lundbeck A/S 03/14/192D 3D TSV
US10125145 31 29 HGNC:5297 5-HT3 receptor antagonists Takeda Pharmaceutical Company Limited 03/12/192D 3D TSV
US10125150 26 26 HGNC:6190 Crystalline forms of a PI3K inhibitor Incyte Corporation 03/12/192D 3D TSV
US9593113 85 83 HGNC:7978 Imide and acylurea derivatives as modulators of the glucocorticoid receptor Bristol-Myers Squibb Company 03/12/192D 3D TSV
US9593121 14 14 HGNC:25581 Indole substituted pyrrolopyrimidinyl inhibitors of Uba6 Millennium Pharmaceuticals, Inc. 03/12/192D 3D TSV
US9593129 497 406 Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer Amgen, Inc. 03/12/192D 3D TSV
US10125148 28 27 Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication ViiV HEALTHCARE UK (NO. 5) LIMITED 03/12/192D 3D TSV
US10125097 18 18 HGNC:9358 1- [1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives UNIVERSITAT DE BARCELONA; FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA); IPROTEOS S.L. 03/11/192D 3D TSV
US10125111 99 97 Benzofuran compounds for the treatment of hepatitis C Bristol-Myers Squibb Company 03/11/192D 3D TSV
US10125137 10 10 Benzofurans substituted with bicyclic secondary benzamide as HCV inhibitors Bristol-Myers Squibb Company 03/11/192D 3D TSV
US10124009 14 7 HGNC:13575 Bromodomain inhibitors Tensha Therapeutics, Inc. 03/11/192D 3D TSV
US10125135 51 47 HGNC:3467 Chemical compounds AstraZeneca AB 03/11/192D 3D TSV
US10123995 32 20 HGNC:3529 Factor XIa inhibitors Merck Sharp & Dohme Corp. 03/11/192D 3D TSV
US10125118 458 450 HGNC:7027 Heteroaryl compounds and their use as therapeutic drugs Dong-A Socio Holdings Co., Ltd. 03/11/192D 3D TSV
US10117875 20 20 HGNC:15633 Immune system modulators JANUS BIOTHERAPEUTICS, INC. 03/11/192D 3D TSV
US10125101 123 45 HGNC:4498 HGNC:2622 HGNC:2623 Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof Boehringer Ingelheim International GmbH 03/11/192D 3D TSV
US10112968 7 7 Inhibitors of protein methyltransferase DOT1L and methods of use thereof Epizyme, Inc. 03/11/192D 3D TSV
US10112955 73 53 HGNC:7110 HGNC:7111 Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 eFFECTOR Therapeutics, Inc. 03/11/192D 3D TSV
US10118894 7 7 Isoindolinone derivatives useful as antiviral agents ViiV HEALTHCARE UK LIMITED 03/11/192D 3D TSV
US10118915 563 548 HGNC:8154 Kappa opioid ligands The Scripps Research Institute 03/11/192D 3D TSV
US10125100 197 73 HGNC:11491 HGNC:11283 HGNC:6251 HGNC:4616 HGNC:6876 Kinase inhibitors Topivert Pharma Limited 03/11/192D 3D TSV
US10125125 58 58 HGNC:10499 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors Active Biotech AB 03/11/192D 3D TSV
US10123984 50 47 HGNC:7154 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC 03/11/192D 3D TSV
US10118929 6 3 HGNC:6161 HGNC:6163 Nonanoic and decanoic acid derivatives and uses thereof SciFluor Life Sciences, Inc. 03/11/192D 3D TSV
US10118918 49 48 HGNC:10894 PRMT5 inhibitors and uses thereof Epizyme, Inc. 03/11/192D 3D TSV
US10118930 465 459 HGNC:9051 Piperidinylpyrazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT 03/11/192D 3D TSV
US10117858 15 13 HGNC:1884 Pyridine and pyrazine derivative for the treatment of CF Novartis AG 03/11/192D 3D TSV
US10125144 60 30 HGNC:10251 HGNC:10252 Rho kinase inhibitors KADMON CORPORATION, LLC 03/11/192D 3D TSV
US10118902 223 210 HGNC:8039 Small molecule agonists of neurotensin receptor 1 SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 03/11/192D 3D TSV
US10117864 67 62 HGNC:9600 Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof BAYER PHARMA AKTIENGESELLSCHAFT 03/11/192D 3D TSV
US10125133 13 13 HGNC:29079 Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors Incyte Corporation 03/11/192D 3D TSV
US10117944 14 14 HGNC:3430 Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. 03/11/192D 3D TSV
US10124003 52 49 HGNC:3689 Therapeutic agent for FGFR inhibitor-resistant cancer Taiho Pharmaceutical Co., Ltd. 03/11/192D 3D TSV
US10112941 441 334 HGNC:13575 Tricyclic compounds as anticancer agents Bristol-Myers Squibb Company 03/11/192D 3D TSV
US10111866 2 2 Compounds as rearranged during transfection (RET) inhibitors GlaxoSmithKline Intellectual Property Development Limited 03/10/192D 3D TSV
US10112934 40 20 HGNC:2160 HGNC:2159 (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles Centrexion Therapeutics Corporation 03/04/192D 3D TSV
US10112931 783 397 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH NOVARTIS AG 03/04/192D 3D TSV
US10112932 62 20 HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 Benzoxazepin oxazolidinone compounds and methods of use Genentech, Inc. 03/04/192D 3D TSV
US10112944 41 37 HGNC:11892 Heterocyclic compounds useful as inhibitors of TNF Bristol-Myers Squibb Company 03/04/192D 3D TSV
US10112940 116 115 HGNC:17071 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 03/04/192D 3D TSV
US10112935 516 247 HGNC:10251 HGNC:10252 Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease Lycera Corporation 03/04/192D 3D TSV
US10112928 32 32 Inhibitors of SYK HOFFMANN-LA ROCHE INC. 03/04/192D 3D TSV
US10112929 379 248 HGNC:10252 Lactams as inhibitors of rock Bristol-Myers Squibb Company 03/04/192D 3D TSV
US10112937 1877 363 HGNC:8537 P2X7 modulators and methods of use Janssen Pharmaceutica NV 03/04/192D 3D TSV
US10112950 116 116 HGNC:29079 Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors Incyte Corporation 03/04/192D 3D TSV
US10112942 1229 555 HGNC:9967 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. 03/04/192D 3D TSV
US10112939 112 103 HGNC:10252 Tied-back benzamide derivatives as potent rock inhibitors Bristol-Myers Squibb Company 03/04/192D 3D TSV
US9586925 22 11 HGNC:108 HGNC:983 1-(dimethylamino)ethyl-substituted 6H-benzo[C]chromen-6-ones against senile dementia NOBEL ILAÇ SANAYII VE TICARET A.S. 03/02/192D 3D TSV
US9586950 104 25 HGNC:4849 HGNC:4848 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists MERCK SHARP & DOHME CORP. 03/02/192D 3D TSV
US10112926 1455 226 HGNC:8979 HGNC:8978 HGNC:8984 HGNC:3942 HGNC:8974 HGNC:8977 HGNC:8976 Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors Novartis AG 03/02/192D 3D TSV
US9586945 38 35 HGNC:7044 Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy AbbVie Deutschland GmbH & Co. KG; AbbVie Inc. 03/02/192D 3D TSV
US9586942 17 17 HGNC:7044 Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy AbbVie Deutschland GmbH & Co. KG; AbbVie Inc. 03/02/192D 3D TSV
US10112895 14 14 Antivirals against molluscum contagiosum virus The Trustees of the University of Pennsylvania 03/02/192D 3D TSV
US9586949 157 78 HGNC:8978 HGNC:8977 Aza-heteroaryl compounds as PI3K-gamma inhibitors Incyte Corporation 03/02/192D 3D TSV
US9586962 903 449 HGNC:4849 HGNC:4848 Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators Janssen Pharmaceutica NV 03/02/192D 3D TSV
US9585879 28 28 HGNC:4617 Heterocyclic GSK-3 allosteric modulators Consejo Superior de Investigaciones Cientificas (CSIC) 03/02/192D 3D TSV
US9586970 27 27 HGNC:8772 Imidazole derivatives Hoffmann-La Roche Inc. 03/02/192D 3D TSV
US10112922 40 19 HGNC:1133 HGNC:6171 Inhibitor of bruton's tyrosine kinase Centaurus BioPharma Co., Ltd. 03/02/192D 3D TSV
US9586948 51 51 HGNC:17967 Inhibitors of IRAK4 activity MERCK SHARP & DOHME CORP. 03/02/192D 3D TSV
US10112899 326 315 Isoindoline derivatives for use in the treatment of a viral infection ViiV HEALTHCARE UK LIMITED 03/02/192D 3D TSV
US9586965 16 4 HGNC:6190 HGNC:6192 HGNC:1133 HGNC:6193 Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases ACEA BIOSCIENCES INC. 03/02/192D 3D TSV
US9586900 121 121 HGNC:4479 Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists Bristol-Myers Squibb Company 03/02/192D 3D TSV
US10111875 18 6 HGNC:6190 HGNC:6192 HGNC:6193 Pyrrolopyrimidine compounds and uses thereof HUTCHINSON MEDIPHARMA LIMITED 03/02/192D 3D TSV
US10112911 75 75 Substituted cyanoguanidines as oral anti-virals ABBVIE INC. 03/02/192D 3D TSV
US10112907 52 13 Substituted indazoles for treating tendon and/or ligament injuries NOVARTIS AG 03/02/192D 3D TSV
US9585881 56 19 HGNC:3528 HGNC:3529 HGNC:3535 Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases ONO PHARMACEUTICAL CO., LTD. 03/02/192D 3D TSV
US9586959 169 110 HGNC:5297 HGNC:17383 HGNC:5184 Substituted tricyclic heterocycles as histamine 4 receptor inhibitors C&C RESEARCH LABORATORIES 03/02/192D 3D TSV
US10106550 6 6 HGNC:270 Aza-phenalene-3-ketone derivative, preparation method thereof, and its application as PARP inhibitor SUZHOU KANGRUN PHARMACEUTICALS INC. 02/24/192D 3D TSV
US10106522 12 12 HGNC:5182 Benzimidazole derivatives as antihistamine agents Faes Farma, S.A. 02/24/192D 3D TSV
US10106552 43 43 HGNC:24615 Compounds inhibiting eukaryotic elongation factor 2 kinase activity Longevica Pharmaceuticals, Inc. 02/24/192D 3D TSV
US10106521 18 9 HGNC:108 HGNC:983 Eckol derivatives, methods of synthesis and uses thereof Phloronol, Inc. 02/24/192D 3D TSV
US10106571 23 22 HCV polymerase inhibitors MEDIVIR AB 02/24/192D 3D TSV
US10106535 45 45 HGNC:14063 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. 02/24/192D 3D TSV
US10106534 274 216 HGNC:29012 HGNC:17071 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 02/24/192D 3D TSV
US10106527 488 237 HGNC:4617 HGNC:3091 Isoquinolin-3-yl carboxamides and preparation and use thereof Samumed, LLC 02/24/192D 3D TSV
US10106501 428 416 HGNC:10260 Nuclear receptor modulators AbbVie Inc. 02/24/192D 3D TSV
US10106557 26 6 HGNC:9475 HGNC:3528 HGNC:3535 Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof NORTH CHINA PHARMACEUTICAL NEW DRUG R&D CO., LTD. 02/24/192D 3D TSV
US10106504 83 68 Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication ViiV HEALTHCARE UK (NO.5) LIMITED 02/24/192D 3D TSV
US10106508 94 47 HGNC:3236 Quinazoline heterocyclic compound as EGFR kinase inhibitor and preparation and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED 02/24/192D 3D TSV
US10106553 70 70 HGNC:4498 Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes Janssen Pharmaceutica NV 02/24/192D 3D TSV
US10106510 60 59 HGNC:15513 Substituted isoxazoles for treating cancer EPIZYME, INC. 02/24/192D 3D TSV
US10106559 152 43 HGNC:6192 HGNC:1133 Substituted tetrahydrocarbazole and carbazole carboxamide compounds Bristol-Myers Squibb Company 02/24/192D 3D TSV
US10100045 36 36 HGNC:1406 3-aryl-2H-pyrazolo[4,3-b]pyridine compounds and their use as AMPA receptor modulators Janssen Pharmaceutica NV 02/21/192D 3D TSV
US10100030 25 13 HGNC:11526 HGNC:2637 Carboxymethyl piperidine derivative KISSEI PHARMACEUTICAL CO., LTD. 02/21/192D 3D TSV
US10100051 14 14 HGNC:1232 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. 02/21/192D 3D TSV
US10100058 717 364 HGNC:1462 Fused heterocyclic compounds as CaM kinase inhibitors Gilead Sciences, Inc. 02/21/192D 3D TSV
US10100048 7 7 HGNC:4617 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors ABBVIE DEUTSCHLAND GMBH & CO. KG 02/21/192D 3D TSV
US10100057 199 198 HGNC:4597 Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same SK BIOPHARMACEUTICALS CO., LTD. 02/21/192D 3D TSV
US10100046 31 30 HGNC:29079 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. 02/21/192D 3D TSV
US10100049 112 27 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 JAK kinase inhibitor compounds for treatment of respiratory disease THERAVANCE BIOPHARMA R&D IP, LLC 02/21/192D 3D TSV
US10100019 177 72 HGNC:6091 HGNC:427 N2-(2-methoxyphenyl)pyrimidine derivative, method for preparing same, and pharmaceutical composition for cancer prevention or treatment containing same as active ingredient Korea Research Institute of Chemical Technology 02/21/192D 3D TSV
US10105349 6 6 HGNC:8777 Organic compounds INTRA-CELLULAR THERAPIES, INC. 02/21/192D 3D TSV
US10105367 304 300 HGNC:8775 Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones DART NEUROSCIENCE (CAYMAN) LTD. 02/21/192D 3D TSV
US9580437 709 243 HGNC:17101 Triazolopyrimidine compounds and uses thereof Novartis AG 02/21/192D 3D TSV
US10100042 12 10 HGNC:4498 [5,6]—fused bicyclic antidiabetic compounds Merck Sharp & Dohme Corp. 02/21/192D 3D TSV
US9580418 156 52 HGNC:19310 HGNC:8987 Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors Incyte Corporation 02/19/192D 3D TSV
US9580423 200 37 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 02/19/192D 3D TSV
US9580396 112 56 HGNC:934 HGNC:933 C6-spiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 02/19/192D 3D TSV
US9580449 298 295 HGNC:1133 Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity Merck Patent GmbH 02/19/192D 3D TSV
US9580415 36 21 HGNC:6251 HGNC:550 Compounds Proximagen Limited 02/19/192D 3D TSV
US9580412 102 21 HGNC:4540 HGNC:1605 HGNC:1607 HGNC:6026 HGNC:6027 Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases GALDERMA RESEARCH & DEVELOPMENT 02/19/192D 3D TSV
US9580432 134 84 HGNC:1133 HGNC:3236 Fused pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. 02/19/192D 3D TSV
US9579320 492 473 HGNC:11491 Inhibitors of syk and JAK protein kinases Portola Pharmaceuticals, Inc. 02/19/192D 3D TSV
US9579407 4 4 HGNC:8772 Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (PDE10A) in mammals TAKEDA PHARMACEUTICAL COMPANY LIMITED 02/19/192D 3D TSV
US9580411 11 10 HGNC:497 Substituted sulfonamide compounds Hoffmann-La Roche Inc. 02/19/192D 3D TSV
US9580442 52 13 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors Karus Therapeutics Limited 02/19/192D 3D TSV
US10098883 105 101 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT 02/18/192D 3D TSV
US10100018 136 83 HGNC:3166 Amide derivatives as lysophosphatidic acid receptor antagonists Takeda Pharmaceutical Company Limited 02/18/192D 3D TSV
US10098902 131 66 HGNC:663 HGNC:664 Arginase inhibitors as therapeutics Mars, Incorporated 02/18/192D 3D TSV
US10100016 53 53 HGNC:17989 Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. 02/18/192D 3D TSV
US10099993 358 176 HGNC:4595 HGNC:4594 Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 02/18/192D 3D TSV
US10098900 5 5 HGNC:1133 Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases ZHEJIANG DTRM BIOPHARMA CO. LTD. 02/18/192D 3D TSV
US10098888 22 3 HGNC:2625 HGNC:3527 HGNC:2622 HGNC:2623 HGNC:2621 Substituted benzene compounds Epizyme, Inc. 02/18/192D 3D TSV
US10093671 40 37 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection Hoffmann-La Roche Inc. 01/23/192D 3D TSV
US9573958 74 73 HGNC:6171 Benzimidazole derivatives as ITK inhibitors PRINCIPIA BIOPHARMA, INC. 01/23/192D 3D TSV
US9572792 5 5 HGNC:3165 Coumarin compounds as receptor modulators with therapeutic utility Allergan, Inc. 01/23/192D 3D TSV
US9572802 96 92 HGNC:1952 Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity Theravance Respiratory Company LLC 01/23/192D 3D TSV
US10093683 74 58 HGNC:3529 Factor XIa inhibitors Merck Sharp & Dohme Corp. 01/23/192D 3D TSV
US10093697 12 11 HGNC:10906 IBAT inhibitors for the treatment of liver diseases TBA 01/23/192D 3D TSV
US9573957 151 151 HGNC:6710 Inhibitors of leukotriene production Boehringer Ingelheim International GmbH 01/23/192D 3D TSV
US9573930 122 119 HGNC:29079 Inhibitors of lysine specific demethylase-1 Celgene Quanticel Research, Inc. 01/23/192D 3D TSV
US9573961 95 88 HGNC:6255 Inhibitors of the renal outer medullary potassium channel Merck Sharp & Dohme Corp. 01/23/192D 3D TSV
US9573943 86 29 HGNC:19310 HGNC:8987 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use Genentech, Inc. 01/23/192D 3D TSV
US10092575 221 217 HGNC:8775 Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds Dart NeuroScience (Cayman) Ltd. 01/23/192D 3D TSV
US10093673 15 13 Tetracyclic pyridone compounds as antivirals Novartis AG 01/23/192D 3D TSV
US9572811 103 89 HGNC:1133 Treatment of dry eye PRINCIPIA BIOPHARMA INC. 01/23/192D 3D TSV
US10093646 286 292 HGNC:6943 HGNC:936 HGNC:992 HGNC:9644 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 Novartis AG 01/22/192D 3D TSV
US10093664 74 72 HGNC:6851 Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease Board of Regents, The University of Texas System 01/22/192D 3D TSV
US10093631 12 6 HGNC:12805 HGNC:17989 Bifunctional compounds and use for reducing uric acid levels Acquist LLC 01/22/192D 3D TSV
US10093658 29 14 HGNC:12805 HGNC:17989 Bifunctional compounds and use for reducing uric acid levels Acquist LLC 01/22/192D